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Abstract  
Cytoplasmic dynein is a retrograde motor protein complex that carries cargo 
such as organelles and growth factors along microtubules from the cell 
periphery towards the peri-nuclear region.  
The cytoplasmic dynein complex is centred around two homodimerised heavy 
chains, within which multiple mutations have been identified in human 
neurological diseases.  
The ‘Legs at odd angles’ (Loa) mouse has a missense ‘T’ to ‘A’ point mutation 
in the cytoplasmic dynein heavy chain gene (Dync1h1), resulting in a 
phenylalanine to tyrosine substitution at position 580. Mice homozygous for this 
mutation die within 24 hours of birth whilst heterozygote’s manifest an age-
related and progressive neurodegeneration.  
Fixed and live-cell microscopy shows aberrant movement of endocytosed 
growth factors in Loa. Retrograde speed is reduced with a distinct lack of the 
fastest moving carriers. Moreover, the overall pattern of movement is altered 
with increased anterograde and side-steps occurring in Loa.  
Impaired endosomal trafficking of growth factors for degradation prolongs the 
activation of extracellular signal related kinases 1 and 2 (ERK 1/2) and 
increases the expression of the immediate early gene c-Fos in mouse 
embryonic fibroblasts. Motor neurons also show increased levels c-Fos 
however this can be induced by starvation, indicating their enhanced 
susceptibility to stress.  
The light chain (KLC) of dynein’s opposing motor - kinesin is one of many genes 
differentially expressed in Loa compared to wild-type. In addition, associations 
of KLC with the dynein complex is altered in Loa.  
Similarities between human neurological diseases and Loa both at the organism 
and cellular level make Loa a valuable tool towards understanding cellular 
mechanisms fundamental to the process of disease. Through understanding 
comes advancement towards therapeutic targets to improve the lives of 
thousands of people worldwide. 
Chapter 1 
 Introduction 
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1.1.1 Motor proteins 
Efficient intracellular transport of organelles, endosomes and other vesicular 
structures is fundamental to morphogenesis as well as the everyday function 
and survival of the cell. There are three families of motor proteins that work co-
operatively to achieve and maintain cellular homeostasis. Kinesins and Dyneins 
bind microtubules (MT) s and move mainly towards the plus end (anterograde) 
or minus end (retrograde) of microtubules respectively. Myosins bind actin and 
move predominantly in an anterograde direction. 
1.1.2 Dynein families 
Two families of dynein exist; cytoplasmic and axonemal. There are distinct 
differences between the two. Axonemal dynein is structurally based around 1, 2 
or 3 non-identical heavy chains and is responsible for cilia and flagella beating. 
Cytoplasmic dynein on the other hand is formed around a core of two identical 
homodimerised heavy chains and is involved in retrograde transport of 
membrane-bound structures, centrosome assembly and cell cycle progression 
(through associations with kinetochores) [1]. 
1.1.3 Cytoplasmic dynein 
Two forms of cytoplasmic dynein exist; 1 and 2. They function as complexes 
centred around heavy chains 1 or 2 (encoded by Dync1h1 or Dync2h1 
respectively). Dynein 1, is abundantly found in all cells containing MTs and is a 
complex formed of dynein heavy chain 1 (DYNC1H1; referred to as DHC from 
this point onward), intermediate (DYNC1I1 AND DYNC1I2; referred to as DICs), 
light intermediate (DYNC1LI1 AND DYNC1LI2; referred to as DLIC), light chains 
(DYNLT1, DYNLT3, DYN1RB1, DYN1RB2, DYNLL1 and DYNLL2; referred to 
as DLCs) and numerous accessory proteins [2]. In contrast dynein 2 is 
distributed similarly to axonemal dynein in cilia and flagella and is a complex 
formed of dynein heavy chain 2, solely in association with light intermediate 
chains [1-4]. Dynein 1 complex is the topic of this thesis and will be the complex 
discussed from this point on. 
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1.1.4 Dynein heavy chains   
Seventy eight exons encode the two ~530 kDa DHCs that homodimerise to 
form the cytoplasmic dynein complex and account for the majority of the1.2 
MDa complex mass [2, 5, 6]. At the carboxy (C) -terminal is a large, 12 nm 
globular ‘head’ consisting of a hexameric ring of adenosine triphosphatases 
(ATPases) associated with diverse cellular activity (AAA+), which are 
responsible for the approximate 350 kDa of each heavy chain mass. AAA+ 
domains (AAA) 1-4 have recognisable Walker A, or P-Loops, required for 
binding ATP. However, only AAA1 and AAA3 have the necessary Walker B loop 
for ATP hydrolysis to occur, thereby generating energy to propel the motor 
along the MTs. Release of ATP from AAA1 is thought to be the predominant 
and essential driver of dynein’s power stroke, however domain 3 has been 
shown to be essential for dynein motility as ATP-induction at this site releases 
dynein from associated MTs [6-9].  AAA2 and AAA4 aid specificity for MT 
binding whilst domains 5 and 6 lack the P-Loop required for ATP binding and 
are considered to have a more structural role [8] and King, S. Dyneins. 2011, 
page 148. C-terminal to AAA6 is a C-sequence with unknown but essential 
motor function. It is thought to interact with AAA4, 5 and/or 6 [10]. 
Protruding, ~180 amino acids downstream of AAA4 are two α-helices that have 
recently been identified as extensions of AAA4 itself. One α-helix runs from 
AAA4 to a small globular ATP sensitive MT binding domain (MTBD) whilst the 
second originates at the MTBD and terminates back at AAA4, Figure 1.1 [11, 
12]. 
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Figure 1.1: Schematic diagram of the dynein motor domain. Linear representation of the six 
AAA+ modules, the MTBD, the linker, and the C-terminus sequence. The region including AAA1 
to the C-terminus folds into a ring-shaped motor core. DIC, DLIC, DLC and accessory proteins 
bind at the cargo-binding tail (adapted from : King, S. Dyneins. 2011 and [14].  
 
ATP-dependent movement between the α-helices results in altered structural 
alignment so that straight and kinked conformations are possible and may 
contribute to the motility of the complex [11]. This ‘stalk’ is measured at <15nm 
in length and ~2 nm in diameter [10, 12].  Recent X-ray structural analysis 
identified a second coiled-coil, thought to be an extension of AAA5 which acts 
as a support ‘strut’ to the stalk but with some flexibility to enable functionality in 
both the straight and kinked conformations of the stalk [11]. 
Opposite the stalk, amino (N)-terminal to AAA1 is a 10 nm linker domain that 
connects the dynein head to the stem or ‘tail’ region [12, 13]. This linker domain 
spans the face of the head from AAA1 where it originates to AAA4 in an un-
primed, post-powerstroke (no ATP bound) state. The primed, pre-powerstroke 
state finds the linker associated with AAA2. Alternative docking positions of the 
linker, likely produce the predominant movement to account for the dynein 
power stroke [8, 12]. 
The N-terminal ‘tail’ is the location of DHC homodimerisation and association 
with DIC, DLIC, DLC and accessory proteins.  
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1.1.5 Dynein power stroke 
As described in 1.1.4, when un-primed or in the post-power stroke state, the 
linker domain of DHC spans the face of the hexameric AAA ring from AAA 1 to 
4. At this time there is a strong affinity between the MTBD and MTs. ATP 
binding releases the MTBD and primes DHC so that the linker domain moves 
near to AAA2, a distance of ~ 17 nm. During this stage MTBD moves further 
along the MT and a weak MT association is made. The release of ADP + Pi 
causes the power stroke in which the linker returns back to its original position 
and the MTBD associates strongly once again with MTs [13, 15], Figure 1.2. 
 
Figure 1.2: A model of the structure and priming stroke of dynein. Six ATPases associated with 
diverse cellular activity AAA+ form a hexamieric ring at the C-terminus of dynein heavy chain. 
The C-sequence ‘C’ interacts with AAA4, AAA5 and AAA6. The linker connects the motor 
domain to the ‘tail’ region and spans the hexameric ring from AAA1 to AAA4 in the ADP-bound, 
unprimed state. When ATP is bound the linker moves to a ‘primed’ position near AAA2, a 
distance of ~17nm. Dynein is strongly or weakly associated with microtubules in the ADP or 
ATP states respectively, Figure adapted from King, Dyneins, 2011, page 148. 
 
Dynein motility is processive, that is, it can take multiple ‘steps’ along a MT 
without detaching. In order to achieve this one head of the motor must remain 
attached to the MT whilst the other moves forward [5]. Average step size has 
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been repeatedly recorded as 8 nm, however considerable variation has been 
observed [5, 16, 17]. Stepping can be coordinated (steps of the same size) or 
uncoordinated (irregular step sizes) although coordination seems to develop 
with larger steps [5,17]. Recent observations using fluorophores to 
independently label the two dynein heads showed that the two motors can pass 
each other alternately in a’ head over head’ fashion but more often will not pass, 
instead one head will take the lead and the second will play ‘catch up’ in what 
has been described as a side-stepping shuffle along the MT. In addition to this, 
asymmetry was detected within the dimerised proteins which indicated that the 
'right’ head was more likely to lead the ‘left’ which, would constitute the lagging 
head [17]. 
Dynein requires two motor heads but not the tail region to establish processivity 
[16] and is thus suggestive of ‘gating’ mechanisms in which one motor head can 
influence the action of the other. Two gating mechanisms have been proposed; 
a ‘polymer gate’ dependent on the rate of MTs association/dissociation and/or a 
‘nucleotide gate’ controlled by a mechanochemical aspect of the ATP cycle [18]. 
Intramolecular tension has been implicated in polymeric gating as in the 
absence of ATP dynein still moves in a minus end direction along MTs under 
constant force [19]. That a pulling force detaches the rear head before forward 
movement occurs implies that both heads are bound to MTs whilst tension is 
applied and that the force on the rear head is greater than that of the leading 
head, propelling the motor forward. Force applied to the dynein motor can 
influence the directional movement. Under low loads <1 pN dynein has been 
shown to take mainly 8 nm steps in a minus-end direction however, as load 
increases to ~7 pN, step size increases although there is an increased 
likelihood of plus-end movement, resulting in net movement that fails to 
advance dynein in a retrograde direction. The co-operation of multiple motors to 
move large cargos likely overcomes this phenomenon [19, 20]. The size of the 
dynein ring (13-15 nm) and stalk (10-15 nm) imply some constraint to result in 
the most frequent 8 nm step. A compact formation in which the AAA rings 
overlap has been suggested as a restraint that can be released into a splayed 
conformation for larger steps to occur [18]. Evidence for these theories are 
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increased force producing larger steps and shortening of the linker region 
connecting the two motor domains results in smaller steps [16, 18, 19]. 
Side steps and backward movements relative to the direction of dynein travel 
have been observed in several studies but are far less frequent and smaller in 
distance than those of the forward movements [5, 17, 20-22]. These alternative 
step movements may be a result of regulation by the opposing motor kinesin as 
there is some evidence that both kinesin and dynein require opposing motors to 
activate one another and that multiple dynein and kinesin motors are bound to 
membranous vesicles at the same time [23]. Although described as a ‘tug of 
war’ between the two motors, it may be better described as co-operative 
regulation by two opposing motors to optimise directional movement through a 
crowded cytoplasm.  
1.1.6 Dynein subunits 
The N-terminal, tail domain of DHC associates with numerous subunits, which 
help stabilise and modulate the complex, interact with accessory proteins and 
confer specificity to cargo.  
The largest of the dynein subunits; DIC is encoded by two genes; Dync1i1 and 
Dync1i2, and in contrast to DHC’s single isoform has many splice variants that 
can be developmental and/or tissue specific [24-26]. For example; tropomyosin-
related kinase receptor B (TrkB) signalling endosomes are transported by 
neuron-specific DIC isoform 1B and not by the ubiquitous DIC 2C [27]. DICs are 
~ 74 kDa, forming both homo and hetrodimers, which bind DHC tail through 
WD40 repeats at DIC C-terminal [24, 27].  The N-terminus binds membranous 
cargo and the regulatory complex dynactin in close proximity. Steric 
interference of the N-terminal cargo-binding domain eliminates membranous 
cargo transport and associations with dynactin [28]. 
The LICs DYNC1LI1 and DYNC1LI2 are estimated to be ~ 53-59 kDa [2] . Four 
bind DHC directly at sites overlapping those of DIC-DHC interactions however, 
there is thought to be no direct interaction between the DIC and DLICs [29]. 
Their location infers a role in cargo binding, which was indeed confirmed by 
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DLIC1 and DLIC2 siRNA experiments in which severe disruption to the late 
endocytic pathway was observed [30]. 
DLCs are encoded by at least six genes Dynlt1 and Dynlt3 (formerly identified 
as Tctex1) Dyn1rb1 and Dyn1rb2 (formerly roadblock) and Dynll1 and Dynll2 
(formerly LC8) [2, 31].  DLCs homo and heterodimeise but only the homodimers 
bind the dynein complex and this occurs via DIC [32]. DLC are ~ 8-20 kDa and 
are reported to participate in cargo attachment by binding intermediate adaptor 
proteins [33-35].  
In addition to isoform and splice variations within the subunits described, 
phosphorylation also acts as a method for determining cargo associations. For 
example; hyperphosphorylation of DLIC1 during metaphase is thought to 
reduce membrane-bound organelle movement whilst the phosphorylation status 
of DIC affects dynein-kinetochore and DIC-dynactin interactions [36-38]. 
1.1.7 Dynein accessory and regulatory proteins 
The dynein complex has multiple regulators and associates, however the most 
relevant to this thesis are dynactin and LIS1 and thus these are the two I will 
describe briefly. 
With a mass of ~1 MDa and 11 subunits, the dynactin complex is the largest 
and essential regulator of dynein function [39, 40].  
The actin-related protein 1 (ARP1) forms the central support to which the 
subunits associate. Subunits range in size from 22-150 kDa, the largest of 
which; p150 (sometimes referred to as p150Glued, due to the Drosphila 
homologue) is the associate of dynein. The association is via DIC and facilitates 
the association of the dynein complex with cargos [41, 42].  
Dynamitin, the p50 subunit of dynactin interacts with p150 and appears to 
stabilise dynactin structure to enable association with dynein. Over-expression 
of p50 results in disassembly of the dynactin complex, impaired dynein 
association and inhibits retrograde movement [43, 44]. In addition, p50 has a 
role in binding intermediates such as Bicaudal to enable, through rab6, the 
binding of Golgi vesicles as cargo [45]. 
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A further example of dynactin-dynein cargo binding is in the late endocytic 
pathway where Rab7-interacting lysosomal protein (RILP) acts as an 
intermediate (perhaps indirectly) to bind Rab7 coated late endosomes to the 
dynein-dynactin complex [46].  
Dynactin can work independently of dynein to organise and stabilise MTs, 
particularly during cell cycle progression, however more often dynactin works to 
regulate dynein, for example by directing dynein to MT plus ends in readiness 
for retrograde transport, or in co-operation with dynein, for example in 
kinetochore and spindle organisation during mitosis and cellular transport [47, 
48]. 
LIS1 is the protein of platelet-activating factor acetylhydrolase 1B α subunit 
(Pafah1b1) gene and along with associated nuclear distribution protein E 
(NUDE) and NUDE-like (NUDEL) are required for dynein activity and cellular 
distribution. LIS1 associates dynein with tubulin. The LIS1-dependent 
association of dynein with tubulin destined for anterograde transport (transport 
tubulin) likely allows ‘transport’ tubulin to act as an intermediate for kinesin-
dependent transport of the LIS1-dynein complex, during which time LIS1 is 
considered to supresses the activity of dynein.  Upon arrival of dynein at its 
destination NUDEL releases the inhibition of LIS1 on dynein activity however 
LIS1 remains associated with dynein and thus is transported back to the minus 
end of MTs by dynein-associated retrograde transport [49]. NUDE and NUDEL 
associate with the dynein complex via DHC directly or via DIC, DLC8 and 
dynactin (via p150) [50]. Mutations in LIS1 are linked to Lissencephaly (see 
section 1.2.5) in which neuronal migration defects exist. During neuronal 
migration the leading process extends with the centrosome ahead of the 
nucleus. MTs are essential for providing polarity not only for the extension of 
neurites but also nuclear migration toward the leading centrosome. LIS1 and 
dynein inhibition alter the separation between the nucleus and the centrosome, 
likely leading to the impaired neuronal migration observed [51]. In addition LIS1 
has a role in kinetochore and spindle organisation during mitosis [52] and 
localisation of membranous organelles [53]. Knock-down of LIS1 has been 
shown to disperse the Golgi and mis-localise lysosomes from the peri-nuclear 
region to the cell periphery. Conversely, EEs were redistributed from the cell 
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periphery towards the cell centre. Knock-down of NUDE and NUDEL had a 
similar effect whilst individual knock-down was less severe [54].  
Figure 1.3 shows schematically how dynein associates are likely to assemble. 
 
 
Figure 1.3: Composition and domain structure of cytoplasmic dynein (adapted from [55]). The 
C-terminal motor or ‘head’ domain is connected to the N-terminal ‘tail’ by a linker region which 
aids in the mechanics of the powerstroke. The ‘tail’ region is where dynein intermediate (DIC), 
light intermediate (DLIC) and light (DLC) chains bind, along with accessory and regulatory 
proteins such as dynactin, NUDE, NUDEL and LIS1. 
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1.1.8 Kinesin superfamily 
Kinesin is a motor protein that predominantly moves in an anterograde 
direction, from the minus end of MTs, in the perinuclear region, towards the plus 
ends at the cell periphery however, there are exceptions that move in a 
retrograde direction.  
At least 45 genes have been identified as encoding the very large kinesin 
superfamily however, the many alternative mRNA splice patterns mean that the 
number of kinesin proteins, known as KIFs, easily surpass the number of 
genes.   
Kinesins are categorised into 15 families, although these families can be further 
grouped into one of three sub families, those with a motor domain at the C-
terminal (C-kinesins), the N-terminal (N-kinesins) or in the middle (M-kinesins) 
of the heavy chain structure. The kinesins that move in an anterograde direction 
usually have their motor at the N-terminus, however kinesins with a C-terminal 
motor are more likely to move retrogradely. M-kinesins, tend to have a role in 
microtubule stability.  
The most studied kinesin, kinesin-1, or conventional kinesin was the founding 
member of the kinesin superfamily tree and will be discusses further in 1.1.9. 
Briefly, kinesin-1 moves in an anterograde direction and has an important role in 
organelle, vesicle and mRNA transport. Other kinesins have roles in vesicle 
transport, chromosome positioning, spindle pole organisation and intraflagellar 
transport. The kinesin genes and families are summarised in Table 1.1, along 
with their cellular function, where known [56, 57] . 
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Gene Family Role 
KIF5A, KIF5B, KIF5C, kinesin-1 vesicle, organelle and mRNA transport 
KIF3A, KIF3B, KIF3C, 
KIF17 
kinesin-2 vesicle, melanosome and intraflagellar 
transport 
KIF13B, KIF13A, KIF1C, 
KIF16A, KIF14, KIF16B, 
KIF1B, KIF1A 
kinesin-3 vesicle transport 
KIF27, KIF7, KIF4A, 
KIF4B, KIF21A, KIF21B 
kinesin-4 chromosome positioning 
KIF11 kinesin-5 spindle pole separation and spindle 
bipolarity 
KIF20A, KIF20B, KIF23 kinesin-6 central spindle assembly and cytokinesis 
KIF10 kinesin-7 kinetochore-microtubule attachment and 
chromosome congression 
KIF19B, KIF19A, KIF18B 
KIF18A 
kinesin-8 chromosome congression 
KIF6, KIF9 kinesin-9 Not known 
KIF22 kinesin-10 chromosome positioning 
KIF26B, KIF26A kinesin-11 Not known 
KIF15, KIF12 kinesin-12 spindle pole organisation 
KIF2C, KIF2B, KIF2A 
KIF24 
kinesin-13 kinetochore-microtubule error correction 
and chromosome segregation 
KIFC1 kinesin-14A spindle pole organisation and cargo 
transport 
KIFC3, KIFC2, KIF25 kinesin-14B Not known 
 
Table 1.1: The kinesin superfamily. The 45 known genes of the kinesin superfamily are 
categorised into their families with an indication of their cellular role (adapted from [56, 57]). 
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1.1.9 Kinesin-1 
Kinesin-1 is predominantly an anterograde motor protein consisting of a hetero-
tetramer of two heavy and two light chains. The heavy chains (KHC) have an N-
terminal motor or ‘head’ domain and a C-terminal tail, separated by a coiled-coil 
region, Figure 1.4 [58].   
 
 
Figure 1.4: A model of kinesin structure. The two dimerised kinesin heavy chains (KHC) of 
kinesin-1 have an N-terminal motor domain and a C-terminal tail, separated by a coiled-coil 
region. Kinesin light chains (KLC) associate with KHC at the C-terminal and it is here that cargo 
associations are made. 
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ATP hydrolysis provides the energy for mobility however, when inactive kinesin 
is in a folded conformation whereby the tail attaches to the head inhibiting the 
release of ADP and interaction with MTs [58, 59]. This prevents the 
unnecessary expenditure of energy and enables co-ordination with other motors 
to maintain homeostasis of cargos within the cell. It also means that the majority 
of kinesin is found in the soluble cytosolic cellular fraction. KHCs have a role in 
cargo attachment [60]. 
Kinesin light chains (KLCs) are encoded in mice by multiple genes. Of these 
KLC-1 is primarily expressed in neuronal tissue and has many different isoforms 
that may play a role in cargo specificity [61, 62]. For example, KLC-1, isoform b 
was shown to be specific for rough endoplasmic reticulum cargo selection and 
KLC-1d for Golgi [63]. Dynein, through DIC may also be one of the cellular 
cargoes of kinesin with KLC-1 having a role in mediating the interaction 
between the two [63]. KLC-1 has six tetratricopeptide repeats (TPR) at the C-
terminus. TPR’s are structural motifs consisting of 34 amino acids, which 
mediate protein-protein interactions and are needed for cargo binding. The N-
terminus has heptad repeats needed for binding to KHC stalk and tail regions to 
stabilize the inactive conformation when no cargo is bound.  
Binding of cargo to kinesin may weaken the inhibition of KHC by KLC so that 
the KHC motor and tail domains can separate, unfolding the structure so that 
the motor domains of the dimer can move closer together, Figure 1.5 [59, 64-
66].    
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Figure 1.5: Conformation changes upon Kinesin activation. When inactive (left), Kinesin-1  is in 
a folded conformation with the heavy chain motor (brown circles) and tail (light brown ovals) in 
close proximity (pink arrow), but the motor domains are pushed apart  (blue arrow). Once 
activated (right), the motor and tail domains are more widely separated (pink arrow), and the 
motor domains come closer together (blue arrow).  Kinesin light chains are not depicted in this 
diagram. Adapted from [59]. 
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1.2.1 Dynein mutations in human disease 
Efficient intracellular transport is important in all cells however the most 
vulnerable are neurons, partly due to the distances involved in transporting 
cargo from the synapse to the perikaryon and the high energy requirement for 
these cells. To date there have been several mutations in either dynein itself or 
its protein partners that have been implicated in several forms of neurological 
diseases in humans.  
1.2.2 Charcot-Marie-Tooth disease 
Charcot-Marie-Tooth (CMT) disease is the most common neuromuscular 
disorder. It is a chronic polyneuropathy thus affecting both motor and sensory 
neurons. There are two sub-divisions to the disease; demylenating (CMT1) and 
axonal (CMT2), resulting from degeneration of the myelin sheath and axons 
respectively. Disease onset is typically during adolescence or early adulthood 
however symptoms can emerge later in life. Although not classified as a fatal 
disease CMT can be severely debilitating. Lower limbs are predominantly 
affected with muscle weakness and malformations, affecting gait and motility 
and as the disease progresses upper limbs can become affected, reducing 
dexterity. CMT is mainly an autosomal dominant disease, but it can also be X-
linked. Numerous genes have been linked to the disease, but in the context of 
this thesis the most noticeable is a missense change in the homodimerisation 
domain of DHC: p.His306Arg (c.917A-G) in a family with CMT2 (OMIM #614228 
[67] 
1.2.3 Intellectual disability linked to DHC mutations 
Recently, Willemsen et al reported two DHC de novo mutations in patients with 
severe intellectual disability (ID) and neuronal migration defects identified using 
a family based exome sequencing approach. Patient 1 (p.His3822Pro, c.11465 
A-C) was a boy with developmental delay and moderately severe ID. He also 
had an abnormal head size and facial deformities, including a prominent 
forehead. He had broad shoulders, hands and feet and an altered gait. 
Morphologically he had reduced muscle tone and tendon reflexes. 
16 
 
The second patient (p.Gly1518Lys, c.4552G-A), a 51 year old woman had 
severe ID and had never been able to speak or walk. The lady was of a reduced 
height and had a small head circumference, small hands and small feet, which 
were clubbed. She had a flattened head and increased distance between her 
eyes. In addition, she had abnormal spine curvature and had developed 
seizures at an early age [14]. 
Both ID mutations and the CMT mutation within DHC cause distinctive 
characteristics of neurological disease with multiple overlapping phenotypes. 
There are however distinct differences between them, perhaps due to the 
location of the mutation, two within the stem domain and 1 within the motor 
(Figure 1.6). All three diseases are thought to be resultant of neuronal migration 
defects and thus highlight the importance of DHC for this function. 
 
 
Figure1.6: Schematic representation of human DYNC1H1, indicating the location of six patient 
mutations. Severe intellectual disability (Patient 1 and 2) [14], a Charcot-Marie-Tooth disease 
[67] causing mutation and three spinal muscular atrophy mutations [68]. The location of four 
neurological mouse model mutations/deletions are indicated, adapted from King, S., Dyneins, 
2011., and [14]. 
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1.2.4 Spinal muscular atrophy 
Spinal muscular atrophy (SMA) affects approximately 6000 people in the UK 
and is a degenerative, inherited disease in which motor neurons of the legs and 
trunk are primarily affected whilst sensory neurons are spared (OMIM 
#158600). There is a rare sub-class of SMA with lower extremity predominance 
(SMA-LED), where solely lower limbs are affected. Recently, target exon 
capture and subsequent sequencing of the 73 genes within 14q32 revealed 
three mutations within DHC in individuals with SMA-LED. The first identified 
was a c.1750 A-C transversion in exon 8 resulting in a p.Ile584Leu substitution. 
Interestingly this mutation is just 2 nucleotides upstream of where the 
p.Phe580Tyr substitution in the Legs at odd angles (Loa) mouse would be 
located in humans. This mouse has been used for a number of years to study 
neurodegenerative processes caused by impaired dynein function, see section 
1.2.10 and Figure 1.6. 
The other two mutations; c.2011 A-G resulting in p.Lys671Glu and c.3170 A-G 
changing p.Tyr970Cys were in exons 8 and 11, respectively, and all were 
located in the tail domain of DHC. Biochemical assays of Ile584Leu indicated a 
disruption of the dynein complex and reduced affinity of the complex for MTs 
during ATP hydrolysis [68]. 
In addition to DHC mutations, alterations in accessory proteins have been 
identified. Phenotypically there is significant overlap to DHC mutations reflecting 
their co-operative nature necessary for effective function. 
The largest of the accessory proteins is dynactin (see section 1.1.7). A 
p.Gly59Ser substitution in the p150 subunit was identified in a family with slowly 
progressing motor neuron disease. Disease onset commenced in early 
adulthood and included breathing difficulties due to paralysis of the vocal folds 
and facial weakness. Lower limbs were affected later [69].  
The mutation was located in the p150 cytoskeletal-associated protein (CAP)-Gly 
motif that binds MTs. Due to evidence that dynactin is essential for dynein 
function and has a role in directing the dynein complex to MTs it is suggestive 
that the p.Gly59Ser mutation in p150 disrupts dynein complex formation and 
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retrograde transport. Moreover, the overexpression of the p50 dynactin subunit 
in mice has been shown to produce a late-onset and progressive 
neurodegeneration due to disruption of the dynein/dynactin complex [69, 70]. 
1.2.5 Lissencephaly 
Lissencephaly is a brain disorder caused by impaired neuronal migration. It 
literally means ‘smooth brain’ due to an absence of normal folds in the cerebral 
cortex and is often accompanied by microcephaly. Individuals affected do not 
survive beyond 10 years of age and have severe developmental delays. This is 
often accompanied by abnormal facial characteristics, mental retardation, 
muscle spasms, difficulty swallowing and seizures. 
Deletion or mutation in the LIS1 gene accounts for a high percentage of 
lissencephaly cases. LIS1, in conjunction with dynein, plays an important role in 
the migration of developing neurons through positioning of MTs within the cell, 
which is disrupted in lissencephaly (OMIM #607432) [71, 72], see also section 
1.1.7. 
1.2.6 Dynein mouse models 
There are four mouse models with alterations in DHC, chromosomal location; 
12q12.55. ‘Cramping 1’ (Cra1), ‘Abnormal rear leg’ (Arl) (unpublished) and 
‘Legs at odd angles’ (Loa), have point mutations generated through N-ethyl-N-
nitrosourea mutagenesis, whereas ‘Sprawling’ (Swl) has a radiation induced 
nine base pair deletion, Figure 1.6 [73, 74]. 
Cra1, Arl and Swl will be briefly described to demonstrate the severity and 
neuron specific nature of mutations within the DHC. Loa will be discussed in 
greater depth in the next section, as it is the mouse under investigation for this 
thesis. 
1.2.7 ‘Cramping 1’ 
Cra1 maps to position 1055, and is within the DHC homodimerisation domain. 
The mutation substitutes tyrosine to cysteine (TAC to TGC) [75] . 
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In 2003 Hafezparast et al reported an 80% loss of anterior horn cells at 
embryonic day (E) 18.5 in Cra1 homozygote (Cra1/Cra1) embryos and the pups 
were unable to survive more than 24 hours after birth, likely due to impaired 
migration of facial neurons resulting in an inability to suckle. They also 
described Lewy-like inclusions in dorsal root ganglia (DRG), similar to those 
seen in Loa (see section 1.2.10) and human forms of Amyotrophic Lateral 
Sclerosis, a late on-set, progressive neurodegenerative disease [75]. Moreover, 
Dupuis et al 2009 reported small DRGs with reduced numbers of axons per 
dorsal root in Cra1 when compared to wild-type. The reduction was mainly of 
large (>5µm) calibre axons and is suggestive of the loss of type 1a 
proprioceptive axons, a phenotype also observed in Loa and Swl mice but to a 
greater extent 76].   
1.2.8 ‘Sprawling’ 
The Swl ‘GCATAGTGA’ deletion from chromosome; 12q12.55 results in a 
substitution of residues 1040-1043 from glycine (GGC), isoleucine (ATA), valine 
(GTG) and threonine (ACT) to an alanine (GCT). It is within the 
homodimerisation and cargo binding domains of DHC. Swl manifests a 
proprioceptive sensory neuropathy with sensory loss from the DRG being much 
greater in the lumber region than the cervical, concurring with a hind limb 
phenotype. There is a 69% and 87% loss of DRG proprioceptive and muscle 
spindles, respectively, in heterozygous (+/Swl) mice by post-natal day 0.5 
(P0.5), but not in E15.5 embryos, indicating that degeneration begins during the 
late stages of embryonic development. α-motor neurons are not altered in 
morphology, number or function and although a 31% loss of nociceptive 
neurons in 13 week +/Swl is observed, it is not enough to affect overall 
nociceptive ability and confirms that proprioceptive neurons are predominantly 
affected. Swl homozygotes (Swl/Swl) are embryonic lethal 77].  
1.2.9 ‘Abnormal rear leg’ 
The Arl mouse is yet to be published but has been investigated within our lab 
for some time. A T-C change in DHC results in a p.Trp1206Arg substitution 
which is embryonic lethal before E10.5. Heterozygotes (+/Arl) have reduced 
tibialis anterior (TA) muscle strength by 1 year of age, which affects gait and 
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when suspended by the tail the mice twist their bodies and clench their feet, 
which is representative of neuromuscular defects. Examination of MNs revealed 
that although overall numbers were not reduced, soma size was 20% smaller in 
+/Arl than in wild-type mice. These neurons also displayed abnormal excitability 
patterns. Although the examination of retrograde transport, using a fluorescent 
fragment of the tetanus toxin (TeNT Hc), did not show any differences between 
heterozygotes and wild type, it has been suggested that Arl may affect the 
binding of DHC to MTs and ATP and subsequently the efficiency of the power 
stroke (A. Philpott, Investigations into the Biochemical and Cellular Biology of a 
Cytoplasmic Dynein Mutation, Abnormal Rear Leg (Arl), DPhil 2010). 
1.2.10 ‘Legs at odd angles’ 
The most studied of the DHC mouse models is Loa, which has a T to A 
transversion, resulting in a substitution of phenylalanine with tyrosine (TTC to 
TAC) at residue 580, in the overlapping homodimerisation and DIC binding 
domains of DHC. The mutation is autosomal dominant and although lifespan is 
not significantly affected, heterozygous (+/Loa) adults do present with 
progressively weakened muscle tone and reduced mobility, as determined by 
SmithKline Beechman, Harwell, Imperial College, Royal London Hospital, 
phenotype assessment (SHIRPA) which, characterises behavioural, locomotive 
and cognitive phenotypes through standardised testing procedures. 
 The mouse was phenotypically characterised due to its clenched paws and 
abnormal limb flexion when suspended by the tail, which is typical of 
neuromuscular defects, Figure 1.7 [78].  
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                                                wild-type                           +/Loa 
Figure 1.7: Wild-type and +/Loa mice suspended by the tail to show the Loa phenotype. 
Original histopathology examination reported a ~75% loss of α-MNs in +/Loa 
adults by 19 months of age and a 50% loss of anterior horn cells in E18.5 
Loa/Loa, moreover, Lewy-like aggregates containing superoxide dismutase 1 
(SOD1), cyclin-dependent kinase-5 (CDK5), neurofilaments and ubiquitin were 
identified in Loa MNs, mirroring those seen in human ALS [75] patients. 
However, MN loss in Loa has since been disputed because, although Ilieva et al 
2008 identified a 10% reduction in the total number of MNs in +/Loa compared 
to wild-type at 11/2 months of age, this loss was found to be a stable loss (no 
further decrease with ageing) and was identified as a loss of γ-MNs rather than 
α-MNs. The neuronal types are distinctly different as γ-MNs synapse with 
muscle spindles (to provide proprioceptive feedback regarding the length and 
position of the muscle), whereas α-MNs innervate skeletal muscle for 
locomotion. Any α-MN loss observed reflected age progression rather than 
being dependent on Loa [75, 79]. 
In the same study there was a clear reduction in the number of myelinated 
sensory axons in +/Loa compared to wild-type throughout the 11/2 to 22 month 
ages observed, although the size of the axons was not affected. In wild-type 
mice there was an age-dependent increase in the larger (>5µm) sensory axons 
however, this age-dependent shift was not observed in +/Loa, resulting in +/Loa 
having 1/4 of the number of these larger axons compared to wild-type. +/Loa 
also have a reduction in the number of small (<5µm) axons. Parvalbumin 
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staining of large, type 1a proprioceptive neurons revealed substantial reductions 
in +/Loa and complete lack of these neurons in Loa/Loa entering the DRGs. 
These findings are in agreement with Chen et al 2007, who found a 42% loss of 
DRG in +/Loa at 13 weeks of age which, was specific to the lumber region, and 
an 86% reduction in the number of muscle spindles. Both Chen et al and Ilieva 
et al found a lack of the proprioceptive, Hoffman’s or ‘H’ reflex in +/Loa.  This 
test measures the time delay between stimulation of type 1a proprioceptive 
sensory neurons and a responding ‘M’ wave in the α-motor fibres. Additional 
testing by Ilieva showed that pain and temperature sensitivity was not affected 
in the +/Loa mice, but there were significant alterations to locomotion, gait and 
strength. In combination, these two studies indicate a proprioceptive deficit in 
the Loa mouse [79, 80]. 
Examination of neuronal migration by injecting the thymidine analogue; 5-
bromo-2’-deoxyuridine (BrdU) into pregnant +/Loa mice revealed defective 
migration of cortical neurons such that instead of forming a distinct layer at the 
plial surface the neurons were more unevenly distributed in the Loa/Loa 
embryos and cortical lamination was severely impaired. Moreover, somal 
translocation and axon extension in migrating neurons was prolonged. Migration 
defects are also observed in the hippocampus [20, 81]. If defective neuronal 
migration is extended to include facial neurons it may offer explanation as to 
why Loa/Loa pups are unable to survive for more than 24 hours and their 
inability to suckle [75]. 
At the cellular level Loa does not affect mitotic functions but a significant 
reduction in high speed retrograde trafficking of membrane bound 
compartments has been observed [20, 75, 81]. Hafezparast et al. used TeNT 
Hc, which utilises the same pathway as Nerve Growth Factor (NGF) to observe 
this speed reduction along with an increased number of stationary pauses in 
Loa/Loa MNs when compare to wild-type. At the molecular level, using quantum 
dot optical trap assays a reduced run length and overall number of long runs 
was revealed. This is reflected in live-cell imaging of late endosome/lysosome 
movement. No difference in DHC step size has been observed [20]. When 
examining Golgi reorganisation following nocodazole treatment it was found that 
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the reorganisation of the Golgi was slower in Loa/Loa, suggesting that the cells 
are particularly vulnerable under stress (nocodazole depolymerizes MTs) [75].  
Biochemical work identified an increased interaction between DLIC1, DLIC2, 
DIC and DHC in Loa/Loa compared to wild-type. Increased affinity between 
DHC and DIC subsequently increased the association of DYNLT1 and DYNLT3, 
DLCs. This altered association between the dynein subunits and subsequently, 
significantly reduces the interaction with p150 dynactin in Loa/Loa (Wenhan 
Deng, Caroline Garrett et al. Neurodegenerative Mutation in cytoplasmic Dynein 
Alters Its Organisation and Dynein-Dynactin and Dynein-Kinesin Interactions. 
J.Biol.Chem.285, 39922-39934) [82]. Altered interactions within the tail region of 
dynein may affect cargo and/or MT associations and is suggestive of why 
retrograde axonal transport is impaired in Loa. Moreover, there is evidence that 
Loa could also affect the motor activity of dynein. An increased affinity between 
DHC and MTs has been observed in +/Loa in the absence of ATP. Conversely, 
MT binding and ATPase activity in +/Loa is reduced in the presence of ATP, 
indicating a reduction in DHC force production and MT association during 
dynein power stroke in these mice [20]. 
With diseases such as SMA-LED, CMT and ID all being linked to mutations in 
DHC, Loa research has the potential to further our understanding in a broad 
collation of neurodegenerative diseases. Although Loa does not show 
behavioural abnormalities as seen in some human patients with DHC 
mutations, there is a mouse model with a mutation in DLIC1 that presents with 
behavioural changes such as increase anxiety [83], highlighting the 
collaborative potential of these mouse models to help in the understanding of 
debilitating and devastating neurological diseases.  
 
 
 
 
 
24 
 
1.3.1 Endocytosis overview 
Endocytosis is a mechanism by which a cell can communicate between cells, 
adapt to intra and extracellular variations and regulate ligand receptors at the 
plasma membrane. Endocytic cargo varies from growth factors (GFs) and their 
receptors to nutrients, extracellular fluid, bacterial pathogens and some viruses 
(for cells of the immune system).  The method of internalisation is largely 
dependent on the size of the cargo. Phagocytosis and macropinocytosis is 
generally initiated by particles >500nm, whereas clathrin-dependent and 
clathrin-independent endocytosis engulfs smaller cargo. Phagocytosis, 
macropinocytosis and clathrin-independent mechanisms will be described in 
brief, whilst clathrin-dependent endocytosis will be discussed in more detail. 
Additional endocytic mechanisms do exist. They are clathrin-independent 
carrier/GPI-enriched endocytic compartments (CLIC/GEEC), interleukin-2 
receptor β (IL2Rβ) and ADP-ribosylation factor 6 (Arf-6) –dependent endocytic 
mechanisms.  As yet there is far less known about the proteins and mechanics 
involved in these latter pathways and they will not be covered here [84]. 
1.3.2 Phagocytosis 
Phagocytosis is predominantly initiated in macrophages, neutrophils and 
dendritic cells of the immune system. Pathogens, apoptotic cells or nutrients are 
presented to receptors in the plasma membrane, which initiate actin 
polymerisation and in some cases signalling cascades such as 
phosphoinositide 3-kinase for cellular growth. Actin polymerisation extends the 
plasma membrane, invaginating the cargo into a phagosome to be transported 
for degradation. To meet the membrane demand for engulfing very large 
cargos, additional membrane can be sought from recycling and late 
endosomes, lysosomes and endoplasmic reticulum. The phagosome proceeds 
through the cell to the lysosome to which it fuses to form a phagolysosome. The 
internal compartment of the phagolysosome is acidic, resulting in content 
degradation [84-86]. 
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1.3.3 Macropinocytosis 
Macropinocytosis or ‘cell drinking’ can occur both on the macro and micro 
(pinocytosis) scales. Both involve the internalisation of extracellular fluid as a 
result of membrane ruffling. Motile cells extend their plasma membrane by actin 
polymerisation and if no substrate is contacted the extension is recycled back 
into the cell, often with the addition of extracellular fluids.  Membrane ruffling is 
controlled by the G-protein Rac and can be in response to external GFs, such 
as epidermal growth factor (EGF) or internal activation of Src family kinase 
(SFK), a non-receptor tyrosine kinase. There is evidence that some membrane 
proteins can be regulated by macropinocytotic depletion [84, 85, 87]. 
1.3.4 Clathrin-independent endocytosis. 
The most studied of the clathrin-independent endocytic mechanisms is that of 
the integral membrane protein caveolin. There are three caveolin proteins; 1, 2 
and 3 (Cav-1, Cav-2 and Cav-3, respectively). Cav-1 was the first to be 
identified and is expressed predominantly in post-mitotic cells. Cav-2 requires 
Cav-1 for correct function and Cav-3 is expressed mainly in muscle cells.  
The association of caveolin proteins to membrane cholesterol results in the 
formation of flask-shaped structures; caveolae, or ‘little caves’ 50-100nm in 
size. Taking up approximately a third of the plasma membrane, they are 
important for the internalisation of proteins, toxins and viruses. Polymerase 1 
and transcript release factor (PTRF or cavin), and serum deprivation protein 
response (SDPR) have recently been identified as being necessary structural 
proteins for caveolae formation and coat structure [88-90].   
1.3.5 Clathrin-dependent endocytosis 
Clathrin was first discovered in 1975 by Barbara Pearse [91]. It has three heavy 
chains of ~180 kDa and each associates with light chains of ~25 kDa to form a 
triskelion structure. These triskelions (with regulation from the light chains) [92, 
93] are able to form extensive pentagonal and hexagonal formations, building 
lattices that encapsulate proteins and lipids from the plasma membrane into 
internalised compartments. They also form to shuttle proteins from the trans-
Golgi network to the endosome. Clathrin cannot bind directly to membranes and 
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thus adaptor or adaptin proteins (AP) are required to bind clathrin and either 
plasma membrane lipid or protein to initiate clathrin coated pit formation [91, 94, 
95].  
There are four major tetrameric mammalian AP complexes; AP-1, AP-2, AP-3 
and AP-4 that have localisation and recognition sequences to bind clathrin and 
other APs, and help confer cargo specificity. Their roles include Golgi vesicle 
trafficking (AP-1 and AP-4), endocytosis of receptors such as transferrin and 
epidermal growth factor (EGFR) from the plasma membrane (AP-2), and 
synaptic vesicle formation (AP-3) [96-98]. Monomeric APs include AP180 and 
CALM (clathrin assembly lymphoid myeloid leukaemia protein), important for 
endocytosis of synaptic vesicles and clathrin coat formation respectively [99]. 
Overexpression of the C-terminal, clathrin-binding domain of AP180 inhibits 
association with PtdIns(4,5)P2 (or PIP2) in the plasma membrane inhibiting 
clathrin coated vesicle (CCV) formation [99]. The AP family is not solitary in its 
role, there are many other adaptor and associate proteins including epsin and 
amphiphysin which assists membrane curvature and recruits the GTPase 
dynamin for scission from the membrane.  
A CCV takes <1 min to assemble and once formed can have an outside 
diameter of ≥ 600 to ≥ 2000 Å (60-200 nm). It is estimated that in cultured 
fibroblasts ~2500 CCVs leave the plasma membrane every minute, resulting in 
a high turnover of plasma membrane components.  
Following CCV internalisation from the plasma membrane, the clathrin 
associate- auxilin binds. Auxillin has binding sites for clathrin, dynamin and AP-
2. In addition, auxillin recruits heat shock protein 70 (Hsp70), an ATP-
dependent enzyme shown to disassemble clathrin coats. Loss of the clathrin 
coat is rapid, ~5 sec after internalisation. The vesicle is now an early endosome 
(EE), Figure 1.8 [99-103].  
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Figure 1.8: Clathrin-dependent endocytosis. Following  ligand binding, receptors such as 
epidermal growth factor (EGF) and transferrin (Trf) are encapsulated into a clathrin coated pit 
with the aid of adaptor proteins such as AP-2. The GTPase dynamin pinches off the vesicle 
from the cell membrane and very quickly the clathrin associated protein, auxillin recruits heat 
shock protein 70 to dissociate the clathrin coat. The vesicle is now an early endosome (EE), 
directed onto cytoskeletal motors by small Rab GTPase (Rab) 5. Sorting of some receptor-
ligand complexes enables fast recycling endosomes (FRE) containing receptors such as Trf 
receptor to be quickly directed back to the plasma membrane by Rab4. Ubiquitinated contents 
is sorted into intraluminal vesicles which, changes the EE to multivesicular bodies (MVB) coated 
in Rab7. Cargo directed back to the plasma membrane in slow recycling endosomes (SRE) are 
directed by Rab11 and remaining contents are sent via a late endosome (LE) to the lysosome 
by Rab9, for degradation. 
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1.3.6 Rab-directed endosomes  
Endosome fate is directed by members of the Ras superfamily; small Rab 
GTPases of which at least 60 have been identified in humans [104]. Rabs bind 
the cytosolic surface of intracellular membranes and in the presence of GTP co-
locate effector proteins to enable actin or tubulin based transport to occur [105].   
Rabs are post-translationally modified by the addition of 1-2 geranylgeranyl lipid 
groups to cysteine residues in their C-terminus, a process is carried out by 
geranylgeranyl transferase (RabGGT) having been recruited via Rab escort 
proteins (REPs). The prenylation produces a lipid anchor for membrane 
insertion [106]. Rabs are held in their ‘inactive’ GDP-bound state by GDP-
dissociation inhibitor (GDI). It is GDI-displacement factors (GDFs) that identify 
specific Rab-GDP-GDI complexes from the cytosol and initiate the release of 
the GDI from Rab-GDP for insertion into the membrane [107]. Guanine 
nucleotide exchange factors (GEF) activate Rabs by exchanging GDP for GTP. 
This facilitates interactions with effector proteins such as molecular motors, 
kinases, phosphatases, coat and tethering proteins, and soluble N-
ethylmaleimide –sensitive factor attachment protein receptors (SNAREs).   
The interactions between Rabs and the dynein complex are plentiful. Examples 
include Rab 4a on the EE that interacts with DLIC1 [108]. Rab7 on the late 
endosome (LE) through RILP associates with p150Glued subunit of dynactin 
[109] and Rab11a on the slow recycling endosome interacts with DLIC1 and 
DLIC2 through the Rab11effector protein FIP3 [107, 110]. These interactions 
target endosomes to the dynein complex for transport to occur. 
Hydrolysis of Rab-bound GTP to GDP by GTPase accelerating protein (GAP) 
deactivates the Rab once its role has been fulfilled and it is removed from the 
membrane by GDI.  
The transition from one Rab to the next likely occurs as a highly organise 
sequence of events in which the recruited Rab (for example; Rab A) is activated 
by its respective GEF (GEF A), Rab A activation recruits the GEF (GEF B) of 
the sequential Rab (Rab B) which, upon activation recruits GAP to the upstream  
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Rab (GAP A) whilst recruiting the GEF (GEF C) for the next Rab downstream, 
Figure 1.9. 
 
 
Figure 1.9: The Rab GEF and GAP cascade. Once RabA is attached to the membrane it is 
activated by its respective GEF (step 1). Active RabA recruits the GEF for activation of it’s 
sequential Rab, RabB (step 2). RabB recruits GAP for RabA deactivation (step 3) and the GEF 
for RabC activation (step 4). RabC activation recruits GAP for RabB (step 5). Adapted from 
[110]. 
EEs are coated with Rab5 which activates the Rab effector protein EEA1 (early 
endosome antigen-1 to enable EE fusion. EEA1 is localised to the cytosolic face 
of the EE membrane after the removal of the clathrin coat. EEA1 is highly 
specific to the EE and is thought to have a role in EE targeting and docking 
[111]. EEs have an internal pH of ~6.4 which is acidic enough to dissociate 
some ligand-receptor complexes, such as the nutrient receptor transferrin, to 
allow fast receptor recycling, directed by Rab4, back to the plasma membrane 
[112]. After activation EGFR is ubiquitinated on its cytosolic surface to mark the 
receptor degradation. Further sorting and compartmentalisation of endosomal 
contents is dependent on endosomal sorting complexes required for transport 
(ESCRT) which, recognise ubiquitin tags on the cytosolic surface of EGFR. 
Hepatocyte growth factor regulated tyrosine kinase substrate (Hrs) (ESCRT 0) 
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sequentially recruits ESCRT I, II and III to the endosomal membrane to 
invaginate proteins destined for degradation into intraluminal vesicles (ILV). The 
formation of the multivesicular body (MVB) is concurrent with a change to Rab7 
coat [113].  The phospho-lipid; lysobisphosphatidic acid (LBPA) which is 
abundant in LE membranes associates with ESCRT machinery via Alix to 
facilitate formation of MVBs [114] whilst the calcium and phospho-lipid binding 
protein annexin-1 is thought to have an essential and specific role down-stream 
of ESCRT for EGFR vesiculation [115]. ESCRT III and the AAA-ATPase 
vacuolar protein sorting-associated (VPS) 4 is recruited to detach the ILV from 
the membrane. Cargo that is not enclosed within the ILV is localised into tubular 
structures that will be slowly recycled back to the plasma membrane, a path 
directed by Rab11 [116, 117]. This process can occur in as little as 4-30 min 
post ligand stimulation [118, 119]. The mature MVB/late endosomes (LE) now 
solely containing particles destined for degradation is directed toward the 
lysosome in the peri-nuclear region by Rab9. The exchange of contents 
between LE and the lysosome is likely through either fusion and/or transient 
“kiss and run” mechanisms [120]. To enable LE/lysosomal fusion events, 
tethering of the two organelles is required. Tethering complexes include the 
homotypic fusion and vacuole protein sorting (HOPS) complex which interacts 
with Rab7, and class C core vacuole /endosome tethering (CORVET) complex. 
HOPS and CORVET have been shown to interconvert by exchange of subunits 
[121]. Following tethering four SNAREs form a trans-SNARE or four-helix 
‘bridge’ in which an arginine (R), and 3 glutamine (Q) residues are contributed 
by each of the; R-SNARE, Qa (syntaxin 7), Qb (VTI1b) and Qc (syntaxin 8) 
SNAREs, respectively. The R-SNARE vesicle-associated membrane protein 
(VAMP) 7 is required for LE/lysosome fusion whereas VAMP8 is associated 
with LE fusion events.  Ca2+ and calmodulin are thought to be responsible for 
the final stages of LE/lysosomal fusion to form a hybrid organelle in which 
degradative events take place. Further mechanisms exist to restore the 
lysosome to its original state [122]. LE acidity is ~6.0-5.0 but in the lysosome 
acidity reaches 5.0-4.5 for effective degradation to occur [112,123]. The whole 
process is complete in ~60 min post internalisation [124].  
Figure 1.8 shows Rab directed endocytosis from the plasma membrane. 
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1.3.7 Dynein and endocytosis 
Dynein is required for efficient transport of endosomes from the cell periphery to 
the peri-nuclear region and efficient sorting of receptors such as EGFR and 
transferrin in the EE [125]. Defects in the latter are a likely consequence of 
altered subcellular location which, in co-operation with kinesin and using 
directional cues from Rabs, enables bidirectionality for efficient delivery of 
recycling endosomes back to the plasma membrane and degradative cargos to 
the lysosome [125, 127].  
Causal disruptions to dynein integrity may involve impaired physical movement 
of the cargo due to DHC mutation or may involve altered associations with 
cargo. As discussed in 1.1.6 and 1.1.7 DIC, DLIC, DLC and dynactin either bind 
directly to membranous cargo such as endosomes or bind through additional 
proteins, or in the case of dynactin facilitate binding. Any mutations in either 
DHC itself or any of its associated subunits and accessory proteins may alter 
protein-protein affinities or cause steric interference, leading to severe 
disruption to the endocytic process. Motor processivity may also be affected. 
One of the consequences of disrupted endocytic trafficking is altered 
intracellular signalling. 
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1.4.1 Intracellular signalling 
In the last section I discussed how, through endocytosis a cell can internalise 
information from its extracellular environment. The information can be in the 
form of a direct signal from another cell or a change in nutrient or fluid 
composition of its environment. I will now look specifically at how the cell 
responds to GF stimulation for survival and proliferation.  
1.4.2 Growth factors 
GFs as their name suggests are important for cellular growth. In addition they 
aid in determining differentiation, development, cell migration, mitosis, 
regeneration and morphology [128 -131]. Impaired GF regulation can result in 
oncogenesis, particularly in proliferative cells, but may also play a role in cellular 
degeneration and/or death in post-mitotic cells such as neurons.  
1.4.3 EGF signalling cascade 
EGFR is one of four members of the ErbB receptor tyrosine kinase (RTK) 
family. RTKs span the plasma membrane and upon ligand binding are 
endocytosed. Signalling from the receptor continues within the cell until the 
receptor is recycled or degraded in the lysosome [132-136]. EGFR ligands 
include amphiregulin, transforming growth factor-α (TGF-α) and EGF.  
EGF binds EGFR in highly proliferative cells such as endo and epithelium. 
Ligand binding initiates autophosphorylation of the receptor followed by 
endocytosis of the ligand-receptor complex. EGF/EGFR is internalised in a 
clathrin-dependent or clathrin-independent manner at low or high levels of EGF, 
respectively [137]. Once receptor activation has occurred the growth factor 
receptor-bound protein 2 (GRB2) is recruited through its SH2 domain. GRB2 is 
a member of the Src-homology 2 adaptor proteins and thus has both SH2 and 
SH3 domains. Through its SH3 domains, GRB2 binds to the guanine nucleotide 
exchange factor (GEF) SOS.  The GEF activity of SOS promotes the 
dissociation of guanosine diphosphate (GDP) from inactive G-protein Ras, so 
that Ras can bind guanosine triphosphate (GTP) to become active. Ras 
activates RAF, a mitogen-activated protein (MAP) kinase kinase kinase 
(MAP3K) which phosphorylates to activate Mek (MAP2K). Mek subsequently 
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phosphorylates extracellular signal-related kinase (ERK) 1 (or MAPK3) on Thr 
202/Tyr 204 and ERK 2 (MAPK2) on Thr 15/Tyr 187 [138, 139]. Phosphorylated 
ERK 1/2 (pERK 1/2) activates downstream transcription factors such as Elk1, 
which binds immediate early gene (IEG) promoters to initiate transcription of 
genes such as c-Fos, c-Jun and c-Myc for a rapid survival response to GF 
stimulation [140], Figure 1.10. 
EGF activation of ERK 1/2 is transient in nature with active, pERK 1/2 levels 
remaining in the cytosol, reducing by 30 min post stimulation and returning to 
basal levels by 60 min [141]. 
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Figure 1.10: Extracellular signal related kinase activated by epidermal growth factor (EGF) or 
brain derived neurotrophic factor (BDNF). EGF or BDNF activate receptor tyrosine kinases; 
EGFR and TrkB, respectively. EGF initiates the Ras pathway resulting in transient activation of 
ERK 1/2 (pERK 1/2), whereas in neuronal cells a sustained activation of ERK 1/2 is achieved by 
initiating Rap1. pERK 1/2 phosphorylates ELK1, which binds the serum response element 
(SRE) of the c-Fos promoter when serum response factor (SRF) is bound. Transcription factor 
25 (TCF25) is a negative regulator of c-Fos expression. 
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1.4.4 Brain-derived neurotrophic factor 
Brain-derived neurotrophic factor (BDNF) is a member of the nerve growth 
factor (NGF) family. BDNF binds TrkB and p75-neurotrophic receptor (p75NTR), 
a member of the tumour necrosis factor family of receptors. The BDNF 
receptors have different effects; TrkB activation aids differentiation and survival, 
whereas p75NTR can induce survival or apoptosis. Receptor expression and 
ligand-receptor affinity regulates this process [128-130]. TrkB, like the EGFR is 
a RTK. Two other Trk receptors; TrkA and TrkC exist, however they are specific 
to other members of the NGF family; NGF and neurotrophin-3 respectively. 
BDNF activation of TrkB activates the ERK 1/2 pathway described above. In 
this pathway, however, Crk is also activated [142]. Crk, like GRB2 is a member 
of the Src-homology 2 adaptor proteins and thus has both SH2 and SH3 
domains. Crk SH3 domain nucleotide exchanger (C3G), which acts as a GEF 
for Rap1 binds Crk for activation and subsequent activation of Rap1 by GDP-
GTP exchange. Rap1 forms a complex with B-Raf to activate ERK 1/2 for 
sustained activity. Thus, acute or gradual GF stimulation may trigger transient 
or sustained activation of ERK1/2, respectively, Figure 1.10 [131, 143-145].  
1.4.5 Linking ERK 1/2 to IEG expression 
Activation of ERK 1/2 via the transient Ras or sustained Rap1 pathways 
described above has a profound effect on the ultimate cellular response. In both 
instances, however, ERK 1/2 phosphorylates to activate ELK1 (p62TCF), which is 
vital for transcription of the IEG c-Fos. 
c-Fos was one of the first IEGs to be identified.  Defined as rapid response 
genes that produce a fast and transient response to growth factors, IEGs are 
important not only in cell growth and proliferation, but also as proto-oncogenes 
in tumourigenesis [146]. The c-fos enhancer region is located around 300nt 
upstream of the transcription initiation site and contains a serum response 
element (SRE) with a 20bp dyad symmetry element [147], to which the 67kDa 
serum response factor (SRF) binds in conjunction with ELK1, to initiate 
transcription of c-Fos [147-149] (Figure 1.10). ELK1 is encoded by Elk-1, Sap1 
or Sap2, which are all ETS-related genes; those containing an ETS DNA-
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binding motif, a SRF interaction domain and a mitogen activated protein kinase 
(MAPK) transcription activation domain [150, 151]. ELK1 forms a ternary 
complex with SRE and SRF to initiate transcription. Binding of SRF to SRE is 
essential for binding of ELK1 [146]. Following transcription c-fos is 
phosphorylated by pERK 1/2 and RSK (90K-ribosomal S6 kinase) on Ser 374 
and Ser 362, respectively. c-Fos dimerises with c-jun, itself activated by c-Jun 
N-terminal kinase (JNK) phosphorylation on Ser 63 and Ser 73. Together they 
form activator protein-1 (AP-1) to enhance the transcription of genes involved in 
cell proliferation [152-154]. 
Phosphorylation of c-Fos on Ser 374 is a result of transient ERK 1/2 activation, 
which returns to basal levels before further phosphorylation can occur. In this 
state c-Fos is highly unstable. This initial phosphorylation does however prime 
c-Fos for further phosphorylation by exposing an ERK docking, DEF domain 
such that subsequent phosphorylation can occur on Thr 325 and Thr 331, if 
ERK 1/2 activity is sustained, resulting in a hyperphosphorylated, stable c-Fos 
[154]. 
Such variation in signal duration is a way in which cells use a single pathway to 
communicate alternate cellular fates. For example, sustained ERK 1/2 
activation causes entry into S-phase in fibroblasts and causes differentiation 
into sympathetic-like neurons in PC12 cells. Moreover, fast and slow delivery of 
GFs can induce transient or sustained responses. Ji et al. reported that fast 
delivery increased both the number of neurites and neurite length in acutely 
activated rat hippocampal neurons, but increased branch points when BDNF 
was delivered gradually [141, 155, 156]. Such differences in morphology and 
mitotic nature highlight the importance of regulating signal duration. 
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1.4.6 Regulating signal duration 
Efficient localisation, degradation or recycling of receptor-ligand complexes 
through endocytosis is vital for regulating signal duration. Although receptor 
activation is initiated at the plasma membrane, there is evidence that receptors 
can continue to activate signalling cascades as they are transported along MTs 
in a dynein-dependent manner thus acting as ‘signalling endosomes’. Any 
impairment to the transport process may result in aberrant signal duration of 
multiple pathways [157, 158].  
The use of scaffold proteins to tether signalling molecules to distinct subcellular 
compartments enables alterations in amplitude and length of signalling. Bringing 
together multiple signalling partners into close proximity allows rapid 
transmission of signal and likely prevents cross-talk between pathways 
(reviewed in [159]). The kinase suppressor of Ras (KSR) and MEK partner-1 
(MP1) are two scaffold proteins important in MAPK signal duration, that are 
mobilised in response to RTK signalling. In quiescent cells KSR interacts with 
MEK1/2 and protein phosphatase 2 (PP2) and is held in the cytosol by the 
molecular regulator 14-3-3 and the Ras-sensitive ubiquitin ligase impedes 
mitogenic signal propagation (IMP). GF activation of Ras results in the release 
of KSR-MEK from PP2 and IMP which, is then free to move to the plasma 
membrane to assemble up and downstream effectors Raf and ERK 1/2, 
respectively [159]. In the case of MP1, regulation of ERK is via MP1-MEK1 
interactions. The adaptor protein p14 associates MP1 with LEs and is essential 
for efficient EGF-stimulated ERK signalling [160]. The membrane protein 
caveolin is an additional scaffold protein that can associate with EGFR, G-
protein coupled receptors, G-proteins, kinases and the ‘sprouty’ family of 
proteins. Sprouty proteins are encoded by the Spry2 gene and have been 
shown to inhibit ERK activity through binding GRB2 and inhibiting the 
recruitment of SOS. Following GF stimulation SPRY1 and SPRY2 translocate to 
the plasma membrane where they are tyrosine phosphorylated within 
approximately 5 min following GF stimulation however maximal phosphorylation 
occurs by 15 min. That Spry can be increased through RTK activity indicates a 
negative feedback for these pathways however post translational modification 
allows precise control. Caveolin may have a role in enhancing the activity of 
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SPRY as SPRY phosphorylation and signal inhibition occur at the plasma 
membrane [161]. 
Phosphatases are more specific regulators of intracellular signalling.  The 
MAPK phosphatase (MKP) family responsible for dephosphorylation of MAPK 
are split into three groups; those that dephosphorylate tyrosine 
(phosphotyrosine-specific protein tyrosine phosphatases [PTP]), including PTP-
SL, striatum-enriched PTP (STEP) and hematopoietic PTP (HEPTP), the 
serine/threonine phosphatases; PP2A and PP2C and the serine/threonine and 
tyrosine (dual specificity phosphatases [DUSP]) of which there are >30 and at 
least 13 of which are dual specific MKPs. Interestingly MKP transcription is 
initiated by MAPK signalling, causing dephosphorylation within the p.ThrXp.Tyr 
activation loop of MAPK and acting as a negative feedback loop for MAPK 
regulation [162]. Increased or decreased phosphatase activity leads to reduced 
or enhanced duration of ERK 1/2, respectively [157,163]  
In addition to the wide-scale regulation through endocytosis and phosphatase 
regulation described above, there is the additional regulatory mechanism of 
altered gene expression. An example of this is transcription factor 25 
(TCF25/nulp1). 
TCF25 is a regulator of c-Fos expression. It belongs to the basic helix-loop-helix 
family but contains a novel DUF654 domain with enhanced transcriptional 
suppressive activities. There is evidence that the repressive activity of human 
nulp1 (hnulp1) occurs through recruitment of histone deacetylases and that the 
DUF654 domain is important for this function. Furthermore expression of hnulp1 
significantly reduced the transcriptional activities of SRF, thus suggesting an 
inhibitory mechanism for prolonged ERK activation as reduced SRF-SRE 
binding would inhibit ELK1 binding and c-Fos expression [164, 165].  
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1.5.1 Autophagy 
There are three major autophagic pathways; macroautophagy, microautophagy 
and chaperone mediated autophagy (CMA). Macroautophagy, from here on 
referred to as autophagy, is a catabolic process in which cytosolic proteins and 
organelles are sequestered into double-membrane bound vesicles 
(autophagosomes), originating from phagophores or isolation membranes, to be 
transported and fused with lysosomes (autophagolysosomes). The contents of 
autophagolysosomes are degraded in preparation for nutrient recycling when 
the cell is under extreme stress such as starvation, UV irradiation and heat 
shock. Microautophagy facilitates general housekeeping functions through the 
degradation of old or damaged organelles and along with pinocytosis is active 
throughout cellular resting states. CMA selectively degrades soluble cytosolic 
peptides with distinctive KFERQ pentapeptide motifs (present in ~25-30% of 
cell proteins), recognised by heat shock cognate 70 (hsc70) chaperone and co-
chaperones for transport to the lysosome for degradation.  
The ~30 autophagy-related genes (Atg) were first identified in Saccharomyces 
cerevisiae, although homologues in other organisms have since been identified. 
Knockdown of many Atgs have been shown to cause cell death in 
Saccharomyces cerevisiae when deprived of nutrients [166, 167].  
Autophagy and cell growth are tightly coupled such that nutrient or growth factor 
deprivation induces the former and reduces the latter. The serine/threonine 
kinase, mammalian target of rapamycin (mTOR) is a member of the 
phosphatidylinositol kinase-related kinase (PIKK) family and is the major 
regulator of autophagy whilst being coupled to control of cell growth.  To 
illustrate this point, mutation of mTOR or inhibition by rapamycin can induce 
autophagy even in nutrient rich conditions [168].  
mTOR forms two complexes mTORC1 and mTORC2. mTORC1 is formed of 
the regulatory associated protein of TOR (raptor), mTOR associated protein 
LST8 (MLST8), also known as G-protein beta subunit like (GβL), proline-rich 
Akt substrate of 40 kDa (PRAS40) and DEP domain-containing mTOR-
interacting protein (DEPTOR). mTORC1 requires association with the small 
GTPase; Ras homolog enriched in brain (Rheb) on intracellular membranes for 
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activity and is inhibited by the tuberous sclerosis complex (TSC 1/2) which, by 
acting as a GAP for Rheb inactivates Rheb by GDP association [169]. mTORC2 
is formed of rapamycin-insensitive companion of mTOR (rictor), MLST8/GβL, 
stress activating protein kinase (SAPK)-interacting protein-1 (Sin1), proline-rich 
repeat protein 5 (PRR5/Protor-1) and DEPTOR [170]. 
mTORC1 is responsible for regulating autophagy in response to nutrient and 
growth factor deprivation, and stress. In favourable conditions mTOR 
associates with and phosphorylates the autophagy-related proteins ATG13 and 
serine/threonine Unc-51-like kinase1 and 2 (ULK1 and ULK 2, the mammalian 
homologues of Atg1), which, inhibits the kinase activity of ULK1 and thus 
phosphorylation of downstream effector; focal adhesion kinase family-
interacting protein (FIP200) and therefore autophagy. mTORC via raptor, 
recruits S6 kinase beta-1(S6K) and eukaryotic initiation factor 4E(eIF4E) 
inhibitor; eIF4E-binding protein 1 (4E-BP1) to regulate protein synthesis and cell 
growth. S6K is also a regulator and inhibitor of autophagy. The activation of 
S6K and 4E-BP1 is through MAP4K3 in reponse to amino acids and although 
not directly affected by rapamycin, is affected by rapamycin treatment 
indicitaing that MAP4K3 likely works downstream of mTOR [169, 171]. 
Autophagic suppression and activation of S6K1 are through distinct mTOR 
pathways as unlike inhibition of mTOR, inhibition of S6K1 does not induce 
autophagy under nutrient conditions.  Moreover, S6K1 is essential for 
autophagy to occur [172].  Whilst mTOR can inhibit autophagy independently of 
S6K1 it may be that the positive regulatory effects of S6K1 and the negative 
regulation from mTOR provide a balance between the initiation of autophagy to 
promote cell survival and extended autophagy leading to autophagy-induced 
cell death [173-175].  
Amino acid (particularly leucine and arginine) or GF deprivation results in a 
reduced cytosolic pool of available amino acids which may affect Rheb-GTP 
levels and thus the activity of mTORC. In addition amino acid deprivation 
inhibits the activity of the endosome associated class III phosphatidylinositol 3-
kinase (PI3K)/VPS34 thereby inhibiting mTOR. Subsequently, ATG13 mediates 
the interaction between ULK1/2 and FIP200 to form two complexes of ATG13-
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FIP200-ULK1 and ATG13-FIP200-ULK2, the latter of which can only form in the 
presence of FIP200 (Figure 1.11). ULK 1 and 2 autophosphorylate as well as 
phosphorylating both FIP200 and ATG13, inducing autophagy. The existence of 
two complexes with differing binding affinities is indicative of distinct roles in 
autophagy, perhaps in the formation of autophagosomes [176, 177].   
 
 
Figure 1.11: mTOR regulation of autophagy.  During nutrient rich conditions mTOR actively 
phosphorylates ATG13 and ULK 1 and 2 to inhibit autophagy. However amino acid deprivation 
results in inhibition of VPS34 and subsequently mTOR. When mTOR is inactive the inhibition of 
ULK 1/2 is released, allowing autophosphorylation. In addition ULK 1/2 phosphorylates ATG13 
and FIP200 which, complex to initiate autophagosome formation.  S6K1 is downstream of 
mTOR and is both an inhibitor of autophagy and essential for its occurrence.  mTORC2 
regulation of autophagy is via the IGF receptor (IGFR) and follows the pattern of inhibiting or 
inducing autophagy when nutrients are high or low respectively. 
 
mTORC2 has been shown to regulate autophagy via the insulin receptor, class 
I, PI3K and protein kinase B(PKB)/Akt. This pathway is a positive regulator of 
mTOR and thus a negative regulator of autophagy. Akt also phosphorylates 
FoxO to inhibit the transcription of autophagy-related genes [168, 178]. 
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1.5.2 c-Jun N-terminal kinase 
The major kinases activated in response to stress are c-jun N-terminal kinase 
(JNK), also known as stress activated protein kinase (SAPK) and p38 kinase. 
Of these, I would like to take a closer look at JNK. 
JNK is encoded by 3 genes; JNK1, JNK2 and JNK3 which produce 10 
mammalian splice variants consisting of 4 from JNK1, 4 from JNK2 and 2 from 
JNK3, JNK3 isoforms being specific to the brain.  
Like ERK, JNK can be activated by cytokines and mitogens. Whereas ERK is 
activated through RAF, the JNK pathway is divergent at the level of Ras, which 
binds and activates MEKK1 (a MAPK subgroup, distinct from Raf) and 
subsequently SEK and then JNK [179, 180]. JNK primarily phosphorylates c-
Jun but also ELK1, a transcription factor up-stream of c-Fos. Together, c-Fos 
and c-Jun form the AP-1 complex and initiate transcription of IEGs for cell 
proliferation and growth.   
JNK is more widely recognised for its activation in response to stress and is 
capable of activating a programme of cell death. This will be looked at in the 
following section along with reports that JNK activation is linked to the formation 
of autophagosomes. Autophagy is often initiated as a mechanism of cell 
survival during times of stress. However, autophagy can also terminate in an 
alternative pathway of cell death.  
1.5.3 JNK initiation of autophagy and cell death 
JNK phosphorylates Bcl2. Bcl2 has been shown to associate with and inhibit 
pro-apoptotic Bax, and pro-autophagy, Beclin1. Following nutrient deprivation 
limited phosphorylation of Bcl2 by JNK releases the inhibitory effect on Beclin1, 
enabling autophagy to be utilised for nutrient recycling. Bcl2 inhibition of Bax 
remains. However, following sustained starvation JNK phosphorylation of Bcl2 
becomes sufficient to disrupt the Bcl2/Bax association so that the cell moves 
into a program of caspase-activated cell death [181, 182].  
In contrast to this there are reports that in response to nutrient or growth factor 
deprivation, JNK has a suppressive role in autophagy and instead, activates 
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FoxO and effector Bcl2 interacting mediator of cell death (Bim) to initiate cell 
death [183, 184].  A similar response has been observed following UV-induced 
cell stress. During favourable conditions Bim is sequestered by DLC and 
myosin V however, phosphorylation-dependent release by JNK activates the 
Bax-dependent mitochondria apoptotic pathway [185].  Moreover, there are 
interesting reports that the inhibition of Bax can ameliorate SMA symptoms in a 
mouse model of the disease [186]. Activation of Bim is dependent on 
cooperative binding of c-Jun, FoxO and Mybs transcription factors, perhaps 
enabling the utilisation of each pathway independently but also ensuring a 
definitive signal for cell death [183].  
Interestingly, up -regulation of c-Fos and c-Jun in lymphoid cell lines, 60-120 
min post nutrient starvation has been observed in cells undergoing programmed 
cell death and inhibition of c-Fos and/or c-Jun is reported to be sufficient to 
increase cell survival in nutrient-deprived cells [187]. c-Fos levels are likely to 
increase simultaneously to c-Jun as JNK phosphorylates ELK1, upstream to c-
Fos. 
From the data discussed here it would seem that JNK is very important in the 
determination of cell fate. There is evidence that JNK activated autophagy may 
promote cell survival yet it may also be an alternative and distinct method of 
class II, autophagic cell death. It is clear that JNK is involved in an intricately 
regulated pathway that has a narrow margin between the ability to save a cell 
under stressful conditions or proceed down a pathway of cell death. The 
ultimate trigger determining cell fate is not clear however, autophagy appears to 
have a clear influence whether as cause or consequence and is implicated in 
the pathology of several neurodegenerative diseases (see section 1.5.4). 
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1.5.4 Autophagy in neurological disease 
Autophagosome formation has been observed in several neurological diseases 
such as Alzheimer’s disease (AD), Amyotrophic Lateral Sclerosis (ALS), 
Parkinson’s disease (PD) and Huntington’s disease (HD) [188]. 
In AD and PD the hallmark pathological features are the accumulation of β-
amyloid (Aβ) peptides, produced by the cleavage of amyloid precursor protein, 
or α-synuclein in Lewy-like aggregates, respectively. In HD toxicity arises from a 
>35 CAG trinucleotide repeat expansion in the Huntingtin (HTT) gene which 
produces an expanded polyglutamine tract at the N-terminus of the protein. All 
of these proteins have been shown to be degraded via autophagy [188, 189].  
In ALS, transactive response DNA-binding protein 43 (TDP43) and Cu, Zn 
superoxide dismutase (SOD1) are two further proteins degraded through 
autophagy. Both TDP43 and SOD1 mutations and aggregates have been 
identified in familial cases of ALS while mouse models overexpressing TDP43 
or transgenic SOD1Gly93Ala have linked such degradation to the autophagic 
pathway. Moreover, inhibition of autophagy results in increased accumulation of 
TDP43 and SOD1 in the respective mouse models, which correlate with 
increased toxicity and cell death [190-192]. 
These findings indicate a neuroprotective effect of autophagy and a potential 
therapeutic target for several neurodegenerative diseases. However, 
autophagosomes have also been identified as a major source of Aβ production 
in AD, resulting in an increased and toxic soluble source of Aβ and 
subsequently disease [189].  
Together, this suggests beneficial effects of autophagy that have the potential to 
be utilised, however due to the distal origination of autophagosomes and their 
spatial dependency for maturation [193], any deficiencies in autophagy 
transport may tip the balance from one of neuroprotection to one of autophagy-
induced cell death.  
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1.5.5 Dynein and autophagy 
Microinjection of anti-DIC antibody into Hela cells has been shown to virtually 
abolish the rapid retrograde movement of autophagosomes and overexpression 
of the p50/dynamitin subunit of dynactin resulted in significant reductions in 
autophagic trafficking [194]. In addition, DLC1 is required for autophagy 
clearance of protein aggregates and for mediation of autophagy-induced cell 
death in Drosophila salivary cells [195].  
Loa DHC mutation has been shown to impair autophagy processing of toxic 
protein aggregates in a Ross/Borchelt mouse model of Huntington’s disease. In 
this model mice express Huntington residues 1-171, including 82 glutamine 
repeats. When crossed with +/Loa, disease progression was enhanced, 
including early onset of muscle tremors and more severe gait abnormalities. 
This coincided with increased toxic aggregates compared to control mice either 
heterozygous for Loa or toxic HD repeats [196].  
These results are suggestive that mutations within DHC, now determined in 
several neurological diseases may well be a major determinant of the neuronal 
autophagy stress response and implicate autophagy as causal in many 
neurodegenerative diseases. The associated signalling pathways, particularly 
JNK likely play a vital role in determining cell fate. 
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1.6.1 Research 
Although previous reports of reduced retrograde transport had been reported in 
Loa there had been little evaluation of multidirectional transport kinetics, which 
is important due to cooperation with kinesin. I hypothesised that overall track 
patterns would be markedly different from those of wild-type, perhaps including 
an alteration in number or speed of anterograde movements. Moreover, that 
such impairment would manifest substantial alterations to cell signalling, due to 
the role of dynein in transporting receptor-ligand complexes for degradation.  
This, in turn would have global effects on gene expression. The staggering size 
and non-proliferative nature of neuronal cells, particularly MNs render them 
more vulnerable to defective transport. I therefore predicted responses to such 
defects would be far more severe than in the robust fibroblast cells on which 
many experiments would be established. 
47 
 
Chapter 2 
Methods 
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2.1 Genotyping 
E13 tails were digested overnight in 100 mM Tris-HCl pH 8.0, 5 mM EDTA, 
0.2% SDS, 200 mM NaCl and 20 µg Proteinase K (New England Biolabs), at 
55°C. Samples were vortexed before centrifugation at 13,000 rpm for 10 min 
and supernatant collected. Qiagen HotStar Taq master mix was used for PCR 
as per manufacturer’s instructions and 0.5 µM of each forward and reverse 
primer; TGCTGTGTGCTCTCCTGTTT and TTTTACAAGCTTGGCTTTGC, 
respectively, added. The PCR cycle was set to denature for 15 min at 95°C 
before 35 cycles of PCR at 95°C for 30 sec denaturation, 62°C for 30 sec 
annealing and 72°C for 1 min elongation, followed by a final elongation at 72°C 
for 10 min. The T to A transversion in Loa introduces an additional Rsa1 
restriction site within the fragment of Dync1h1 amplified by PCR products and 
thus PCR products were digested with Rsa1 (New England Biolabs) for 2 hours 
at 37°C. Products were run on a 2% agarose gel to identify the genotypes. 
Product sizes and a representative gel are shown in Figure 2.1. 
a 
 672bp 537bp 135bp 24bp 
wild-type +   + 
Loa/Loa  + + + 
+/Loa + + + + 
 
 
Figure 2.1: Genotyping the Loa mouse. a and c) Loa introduces a second Rsa1 restriction site 
to the partial Dync1h1 PCR product. Wild-type mice have PCR products of 672 and 24 bp, 
+/Loa have 672, 537, 135 and 24 bp products and Loa/Loa have 537, 135 and 24 bp products. 
b) A representative gel showing the digested PCR products for the three genotypes. Because of 
their small size, the 24 bp products are not visible on the agarose gel. 
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2.2 Dissection, cell culture and cell assays 
2.2.1 Motor neuron dissection, dissociation and culture 
All cell culture media was purchased from Gibco and chemicals from Sigma, 
unless otherwise stated. 
E13 embryos were removed from the uterine horn on ice and in Dulbecco’s 
phosphate buffered saline without calcium or magnesium (DPBS–) and 
supplemented with 1% penicillin/streptomycin (Figure 2.2a). The brain and tails 
were removed and snap frozen in liquid nitrogen for further analysis or 
genotyping respectively (see section 2.1 for genotyping protocol). 
 
Figure 2.2: Motor neuron dissection from E13 mice embryos. a) An E13 embryo removed from 
its embryonic sac. b) Embryos were placed on their sternum to visualise the spinal column. c) 
Skin was removed and the spinal column dissected away from the remaining embryo. d) Spinal 
column with ribcage and vertebrae clearly visible. e) The spinal cord was removed from the 
vertebrae. f) Extracted spinal cord. Arrow indicates dorsal root ganglia (DRG). g) Opening of the 
spinal cord to reveal the MNs along the midline. h) Removal of DRG. Arrow indicates a section 
where DRG have been cut away. 
 
The body was placed on its sternum with dorsal side uppermost, using the limbs 
to stabilise (Figure 2.2b). The spinal column was clearly visible. Skin overlying 
the spinal column was removed and careful dissection resulted in removal of 
the spinal column from the surrounding tissues (Figure 2.2c-d). The column was 
turned on its side to separate the spinal cord from the vertebrae (Figure 2.2e), 
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before orientating the spinal cord, dorsal side uppermost (Figure 2.2f) to open 
up the spinal cord for removal of DRGs (Figure 2.2g-h). The ventral root 
containing the anterior horn cells was transferred to a 15ml falcon tube 
containing fresh DPBS– with antibiotics and kept on ice while the remaining 
embryos were dissected. 
Following dissection, DPBS– was removed from the spinal tissue and replaced 
with 1 ml HBSS, 1% penicillin/streptomycin and 0.025% trypsin. Samples were 
incubated at 37ºC for 10 minutes with occasional agitation. The solution was 
then removed and 1 ml of complete L-15 media (L-15 media containing 1% 
glucose, 1% penicillin/streptomycin, 20 µM progesterone, 5 µg/ml insulin, 
100mM/ml putrescine, 100 µg/ml coalbumin, 30nM/ml sodium selenite, 2% 
horse serum) with 0.4% bovine serum albumin (BSA) and 100µg DNaseI 
(Sigma #DN25) was added. The tissue was dissociated by pipetting 8 times and 
then allowed to settle for 2 min before the supernatant containing the cells was 
collected and transferred to a fresh tube. 1ml complete L-15 media with 0.4% 
BSA and 20 µg DNase was added to the pellet and triturated a further 8 times, 
allowed to settle, supernatant removed and added to the previous collection. 
900µl complete L-15 media was added to the remaining tissue and a final 
dissociation carried out before removal of the supernatant and disposal of the 
remaining pellet.  
The pooled supernatants were spun through a 1ml 4% BSA cushion at room 
temperature for 5 min at 390 xg. The supernatant was discarded and the pellet 
resuspended in 600 µl MN culture media (Neurobasal media plus 1x B27 
supplement, 0.25% glutamine, 0.1% β-mercaptoethanol, 2% horse serum, 0.1% 
fungizone, 1% penicillin/streptomycin). Cells were added to Lab-Tek II chamber 
slides (Fisher #155379) or coverslips, pre-coated with poly-D-lysine (Sigma 
#P7280) and motor neuron culture media was added to make a final volume 
appropriate for the culture vessel. Media was supplemented with 0.1 ng/ml 
GDNF (R & D systems), 0.5 ng/ml CNTF and 0.1 ng/ml BDNF (Invitrogen) and 
cells were incubated at 37ºC in 5% CO2.  
After 24 hours half media was removed and replenished with fresh. The cells 
were then left undisturbed until day three when 7µM Cytosine β-D-
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arabinofuranoside hydrochloride (Sigma #C6645) was added to the culture. 
MNs were left to mature for at least 1 week, but not more than 10 days before 
experimental data was obtained. 
2.2.2 Establishment and culture of Mouse embryonic fibroblasts 
E13 embryos were dissected from the uterus of a culled +/Loa female, and 
placed in ice-cold DPBS–. Following complete removal of the placenta, the brain 
and red organs were removed. The remaining tissue was minced using a 
scalpel blade and subsequently digested in 2 ml trypsin-EDTA (0.05% trypsin 
and 0.53 mM EDTA 4Na) for 15 min, with occasional agitation. An equal volume 
of complete Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 
15% Hyclone (Fisher), 1% Penicillin/Streptomycin and 1% L-Glutamine was 
added to neutralise the trypsin and the cells were centrifuged for 5 min at 
390xg. Cells were resuspended in complete DMEM and cultured in a 37C 
incubator with 3% O2 and 5% CO2.  
2.2.3 Cell assays 
Starvation of MEFs and MNs was for 2 hours using MN culture media without 
the addition of horse serum (MN starvation media) or complete DMEM without 
the addition of bovine serum (DMEM starvation media) for MNs or MEFs, 
respectively.   
BDNF at a concentration of 5ng/ml was used for MN stimulation and this was 
applied either as a 10 min ‘pulse’ for live-cell imaging or left in situ as 
‘continuous’ stimulation for cell signalling assays. 40µg/ml pHrodo-dextran 
(Invitrogen) was simultaneously applied for live-cell imaging.  
EGF was used for stimulation of MEFs at a concentration of 20 ng/ml and was 
applied either as a pulse for cell fractionation or continuous stimulation for other 
biochemical analysis. Stimulation for microscopy was a 10 min pulse of EGF-
AlexaFluor546 (Molecular Probes) for Live-cell imaging, or EGF-AlexaFluor555 
(Invitrogen) for fixed-cell imaging (to prevent bleed through with other 
fluorophores used, see section 2.5).  
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For live-cell imaging MNs and MEFs were rinsed and replenished with warmed 
MN and MEF starvation media respectively, however the neurobasal media or 
DMEM was replaced in both instances with Leibovitz L-15 CO2-independent 
media. Imaging was undertaken at 37°C. 
2.3 Biochemistry 
All chemicals and reagents were from Sigma unless otherwise stated. 
2.3.1 Cell lysis and tissue homogenisation 
For whole cell lysates or homogenisation of E13 brain tissue, where extraction 
of nuclear contents was important, lysis was in 25 mM tris-HCl, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1% NP-40, 5% Glycerol, 1x protease inhibitors and 10 µl/ml 
phosphatase inhibitors 1 and 2 (Sigma). For brain homogenisation in which 
nuclear disruption was not essential, brains were homogenized in a Dounce 
homogeniser with DPBS–, protease and phosphatase inhibitors as above. A 
volume 9x weight of tissue was used. All lysates were incubated on ice for 15 
min before being vortexed and centrifuged at 13,000 rpm in a table top 
Eppendorf microcentrifuge, set at 4°C. Supernatants were collected and, where 
possible, protein concentrations were determined using a Pierce BCA Protein 
Assay Kit. In situations of very low protein or small sample volume, equal 
volumes were loaded onto electrophoresis gels. 
Subcellular Cell fractionation was carried out using the Calbiochem 
Proteoextract Subcellular Proteome Extraction Kit, as per the manufacturer’s 
instructions. 
2.3.2 λ-Protein phosphatase treatment 
λ-Protein phosphatase (New England Biolabs) treatment of cell lysates was 
carried out as per manufacturer’s instructions and incubated at 30°C for 30 min.  
2.3.3 Immunoprecipitation 
Immunopreciptiation was carried out at 4°C with ice cold buffers throughout. 
Protein A-Sepharose beads (Zymed Laboratories Inc.) were washed twice in 
ice-cold PBS- and centrifuged at 3,000 rpm for 2 min to collect the beads. 
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Beads were then washed with DPBS– containing 1x protease inhibitors and 10 
µl/ml phosphatase inhibitors before being incubated for 2 hours with 0.05 µg/ml 
mouse anti-dynein cytoplasmic 74.1 kDa monoclonal antibody (a generous gift 
from Dr Kevin Pfister, University of Virginia) or mouse IgG (Millipore #PP54) 
control under gentle agitation. Meanwhile brain homogenates were pre-cleared 
by incubating with washed beads and gently agitating for 1 hour.  Brains were 
homogenised using a Dounce homogeniser in buffer without detergent or high 
salt concentration. This would enable identification of altered protein-protein 
interactions which otherwise could be substantially altered by detergent and salt 
[82]. 
Antibody bound beads were collected by 2 min centrifugation at 3,000 rpm and 
were then washed in DPBS– to remove any free antibody. Cleared brain 
homogenates were separated from the beads by 5 min centrifugation at 13,000 
rpm and equal amounts of brain extract from Loa/Loa and wild type were added 
to the antibody beads for incubation overnight, with gentle shaking. Beads were 
collected by centrifugation at 2,000 rpm for 2 min and washed three times in 
DPBS–. They were then washed for 10 min in H2O by rocking and finally spun at 
13,000 rpm for 5 min to collect the beads. Proteins were re-suspended into 
SDS-PAGE sample loading buffer (0.125 M Tris-Cl, 4%  sodium dodecyl 
sulfate, 20% v/v glycerol, 0.2 M dithiothreitol (DTT), 0.02% bromophenol blue, 
pH 6.8, made up in double distilled H2O) by boiling for 5 min, and equal 
volumes were loaded onto a gel for westernblot analysis. 
2.3.4 Immunoblotting and analysis 
Precast NuPage 4-12% density gradient gels (Invitrogen) were used for all 
westerns other than those of KLC-1, for which homemade 10% SDS page gels 
were used. Proteins were transferred to a Hybond-LFP PVDF membrane 
(Amersham Bioscience) at 110 V, for 75 min at 4°C. Membranes were blocked 
in wash buffer (PBS – 0.2% Tween 20) supplemented with 5% non-fat milk for > 
60 min and then rinsed in wash buffer before the application of the primary 
antibody in appropriate wash buffer and incubation period (Table 2.1). 
Membranes were then washed once in wash buffer for 15min at room 
temperature and then 3 times for 5 min each with rinses in between washes 
before appropriate secondary antibodies (Table 2.1), were applied for 45 min at 
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room temperature. Repeat washes were applied and either Western Lighting 
Enhanced Chemiluminescent Luminal Reagent or CDP-Star chemiluminescent 
substrate (Sigma) was applied appropriately to allow detection on film. 
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primary antibody dilution and 
incubation 
buffer 
incubation 
time and 
temp 
secondary antibody, dilution 
and incubation buffer 
phospho-p44/42 MAPK 
(ERK 1/2) Thr 202/Tyr 204 
(New England Biolabs 
#4377S) 
1:1,000  
WB+ 5% 
BSA 
O/N 4°C anti-rabbit HRP (GE 
Healthcare)1:10,000 
WB+ 5% non-fat milk 
c-Fos 
(Santa Cruz Biotechnology 
sc-52) 
1:400  
WB+ 5% 
BSA 
O/N 4°C anti-rabbit HRP 1:10,000 
WB+ 5% non-fat milk 
phospho-SAPK/JNK 
T183/Y185 
(Cell Signalling  #9251S) 
 
1:1,000 
WB+ 3% 
BSA 
O/N 4°C anti-rabbit HRP 1:10,000 
WB+ 5% non-fat milk 
β-actin 
(Sigma A5316) 
1:15,000 
WB 
60 min R/T anti-mouse HRP  
(Dako Cytomation)1:30,000  
WB 
Phospho-XRCC1S485/T488 
(Bethyl Laboratories S461) 
1:3,000 
WB 
60 min R/T anti-rabbit HRP 1:10,000  
WB 
KLC1 
(Santa Cruz Biotechnology 
sc-25735) 
1:200  
WB 
60 min R/T anti-rabbit HRP 1:10,000  
WB 
DIC 
(gift from Dr Kevin Pfister) 
1:1,000 
WB 
60 min R/T anti-mouse AP (Sigma)1:10,000 
WB 
Calnexin 
(Santa Cruz Biotechnology 
sc-6465) 
1:1,000 
WB+ 5% 
BSA 
O/N 4°C anti-goat AP (Sigma)1:10,000 
WB 
α-tubulin 
(Upstate 05-829) 
1:2,000  
WB 
60 min R/T anti-mouse HRP 1:10,000 
WB 
TCF25 
(Sigma AV47624) 
1:400  
WB+ 5% 
BSA 
O/N 4°C anti-rabbit HRP 1:10,000 
WB + 5% non-fat milk 
 
Table 2.1: Antibodies for immunoblotting.  WB = wash buffer, O/N = overnight, R/T = room 
temperature, HRP = Horse radish peroxidase, BSA = Bovine serum albumin, AP = Alkaline 
phosphatase. All secondary antibodies were applied for 45 min at R/T. 
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For the blocking peptide assay the c-Fos blocking peptide (Santa Cruz sc-52) 
was incubated at room temperature for 30 min with the c-Fos antibody at a final 
concentration of 1µg/ml, before being added to the protein-bound membrane 
and protocol continuation as for c-Fos immunoblotting outlined above. An 
immunoblot without the blocking peptide was run in parallel to determine the 
specificity of the antibody. 
Films were scanned using an Epson Perfection 4990 Photo scanner and 
Quantified using ImageJ gel analysis software. Data was transferred to Excel, 
GraphPad and Adobe Illustrator for data representation and statistical analysis. 
2.4 Immunocytochemistry 
All reagents and antibodies were diluted in DPBS- and all washes carried out 
using DPBS-. Cells were washed twice and fixed in 4% paraformaldehyde for 
15 min. Then, 0.1% Triton X-100 was applied for 5 min to permeabilise the 
cells, which were then blocked for 60 min in 2% BSA. The cells were then 
stained with anti-α-tubulin (Upstate) at 1:2000, Islet1 and Hb9 at 1:200 
(generated by Dr Wenhan Deng from hybridoma cells obtained from the 
developmental studies hybridoma bank), or MAP2 (Chemicon International) at 
1:500 dilution, where applicable, for 30min at room temperature before being 
washed three times and applying AlexaFluor 488 conjugate anti-mouse 
(Molecular Probes) at 1:200 for 30min. Coverslips were then washed three 
times and either mounted using Prolong gold anti-fade reagent with DAPI 
(Invitrogen) or incubated with Draq5 (Cell Signalling) at 1:1,000 dilution for 5 
min before being rinsed and mounted using Prolong gold anti-fade reagent 
(Invitrogen). 
2.5 Image acquisition and microscopy analysis 
Live-cell images were collected at 10 min and 30 min post removal of growth 
factor and tracks measured required an overall net retrograde migration to be 
included in the analysis. EGF-AlexaFluor546 images were captured with a 100X 
objective, using a TRITC filter (ex. 490/20, em. 528/38) from a 0.2 sec exposure 
at 100% transmission and a time-lapse of 2 sec for 1 min duration. The MN 
images were acquired with a 100X objective using a 0.08 sec DIC exposure at 
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100% transmission and 1 sec exposure, 100% transmission for TRITC with a 3 
sec time-lapse for 2 min using an Applied Precision personal Delta Vision 
microscope. The Image J ‘Manual Tracking’ plugin (Fabrice P.Cordelieres) was 
used to gather track information. 
For EGF assays fixed-cell images were obtained using FITC (ex.490/20 
em.528/38), Cy5 (ex. 640/20 em. 685/46) and DAPI (ex. 360/40 em.457/50) 
filters and a 60X objective, on an Applied Precision Core Deltavision 
microscope. Exposures were 0.025 sec, 5 sec and 0.05 sec respectively at 
100% transmission. Exposures were uniform for all images.  
Deconvolved images were analysed with the aid of standard image J programs. 
For this; images were converted to 8-bit and following subtraction of 
background fluorescence, a standard threshold was set for all images analysed 
such that particles over the threshold were counted. The polygon drawing tool 
was utilised to measure the area of the cells, visualised using FITC to capture 
α-tubulin staining. 
Both live-cell imaging and EGF assays were analysed with the assistance of 
Excel and GraphPad. A Mann-Whitney U test was applied to determine 
significance. 
Kymographs were produced using software from the MacBiophotonics ImageJ 
for microscopy users. Adobe Illustrator was utilised for data representation. 
2.6 RNA extraction, reverse transcription and qRT-PCR 
For qRT-PCR, RNA was extracted using the NucleoSpin II RNA extraction kit, 
and cDNA was generated using the Promega reverse transcription system. 
Gene sequences were found in the National Centre for Biotechnology 
Information (NCBI ID no’s:TCF25:66855, KLC1:16593, 18S:19791) data base 
and were cross-referenced using a Basic Local Alignment Search Tool (BLAST) 
to those found on the Protein Knowledgebase UniProtKB) data base. Primers 
were designed from this information using the Invitrogen primer design tool. 
qRT-PCR was carried out by adding 2x QuantiTect SYBR Green PCR master 
mix (Qiagen) to 1 mM each of forward and reverse primers in Table 2.2. 
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Gene forward Primer reverse Primer 
18S gccgctagaggtgaaattctt cattcttggcaaatgctttcg 
KLC1 tcttcccaaatgacgaggac ctgtacaccagggccaagat 
Tcf25 cctgatacagcaggcactca tgacctccccaggtacagac 
 
Table 2.2: qRT-PCR primers. Primers for the two genes of interest, KLC1 and TCF25 along with 
the 18S control. 
 
1.5 µg cDNA was required per reaction and the overall reaction volume was 
made up to 30 µl with RNase free water. A Stratagene Mx4000 qPCR machine 
was set to denature at 95ºC for 15 min before 40 cycles of 94ºC denaturation 
for 30 sec, annealing at 56ºC for 30 sec and elongation at 72ºC for 30 sec. A 
dissociation curve followed each real-time cycle.   
 
All data sets were collected from at least three brains for each genotype. Each 
qRT-PCR reaction was carried out in triplicate with at least three reactions for 
each gene. For analysis the mean CT of the 18S triplicates were calculated for 
each genotype and the means were subtracted from each genotypes individual 
triplicate CT for the gene of interest to give a calibrated ΔCT. The mean ΔCT of 
the wild-type was then subtracted from the ΔCT of each genotypes gene of 
interest ΔCT to give a comparative ΔΔCT. To calculate a fold change, the ΔCT 
of the wild-type gene of interest triplicates was divided by the mean ΔCT of the 
wild-type resulting in a mean value of 1. A fold change for the other genotypes 
was calculated by 2-ΔΔCT for each triplicate. Fold change significance was 
analysed across the experiments using GraphPad Prism [82]. 
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Chapter 3 
Endosome trafficking is aberrant in Loa. 
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3.1 Introduction 
Dynein is an essential retrograde motor protein. The p.Phe580Tyr mutation in 
the Loa mouse produces a significant neurodegenerative phenotype with many 
similarities to human disease. Although the precise sequence of events leading 
to neuronal migration defects and neurodegeneration are yet to be determined, 
we can use multiple tools to observe intracellular events that likely contribute to 
the disease process. 
The aim for this chapter was to determine whether the Loa mutation would 
affect the intracellular transport of endocytosed GF-bound receptors. To this 
end, I have used a cohort of fixed and live cell microscopy to analyse endosome 
movements in wild-type and Loa MEFs and primary MNs.  
3.2 EGF time course in MEFs 
Using fluorescently conjugated epidermal growth factor (EGF-Alexa Fluor555), 
it was possible to compare the localisation of endocytosed receptor-ligand 
complexes in wild-type and Loa/Loa MEFs. Cells were starved for 2 hours 
before being stimulated with 20ng/ml EGF-Alexa Fluor555 for 10 min. The cells 
were then rinsed and fixed for imaging at 0, 10, 30 and 60 min chase using an 
Applied Precision Core DeltaVision microscope (exact parameters for imaging 
can be found in section 2.5). Cells were stained for α-tubulin to determine the 
outer boundaries of the cells and 15 cells per genotype and time point were 
analysed (Fig. 3.1). 
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Figure 3.1: EGF-Alexafluor555 processing is altered in Loa MEFs. a) Representative images of 
EGF-Alexafluor555 in wild-type and Loa/Loa MEFs following a 10 min pulse. Images taken at 0, 
10, 30 and 60 min chase show increased numbers of EGF-containing vesicles in Loa/Loa 
compared to wild-type over time.  b) Quantification of the number of EGF-Alexafluor555 vesicles 
remaining at each chase time n=15. c) Average area analysed for vesicle counting was the 
same in wild-type and Loa/Loa, n = 37. 
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At 0 min chase both wild-type and Loa/Loa had similar numbers of EGF-
containing vesicles: 746.9±103.8 and 781.9±74.89 respectively (all deviations 
are given as standard error of the mean (SEM) unless otherwise indicated) (Fig. 
3.1a-b). However by 10 min chase there were significantly more EGF-
Alexafluor555 containing vesicles remaining in Loa/Loa when compared to wild-
type (wild-type = 454.6±34.6, Loa/Loa = 753.5±71.2 and P = 0.0014**).  
By 30 min a distinct reduction in particle numbers in both genotypes was 
apparent, although, quantification remained higher in Loa/Loa than in wild-type 
(289.5±29.3 and 231.529.3± 26.9, respectively). The 60 min chase highlighted 
significance once again with wild-type particles having reduced to 108±10.1 and 
Loa/Loa to only 148.1±9.9 (P = 0.0152*). This may indicate a delay in EGF-
AlexaFluor546 degradation however, due to the prominent difference at 10 min 
chase these findings may indicate a delay in EE fusion and MVB formation 
(Figure 3.2a-b).  
To ensure that the number of particles was not simply a measure of the area 
analysed, 37 cells from each genotype were measures to check that the 
average area used for analysis was the same for each genotype. No significant 
difference was found (wild-type = 2057µm2±89.29 and Loa/Loa = 
1992µm2±86.72) (Figure 3.2c).  
3.3 Live-Cell Imaging of EGF in MEFs 
To gain further insight into vesicular movement during trafficking, live-cell 
imaging was carried out. 
The same protocol as in 3.2 was implemented, but instead of fixing the cells, 
they were rinsed and left in warmed CO2-independent DMEM starvation media 
for imaging at 10 min and 30 min chase (exact imaging parameters can be 
found in section 2.5). EGF-Alexafluor546 movement was tracked using Image J 
manual tracking plugin (Fabrice P.Cordelieres) (Figure 3.2a-c.)  
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Figure 3.2: Endosome trafficking is aberrant in Loa. a) Frame sequence of EGF-Alexafluor546 
movement in a wild-type MEF. b) Representative tracks from wild-type and Loa/Loa MEFs. The 
Loa/Loa path appears shorter and more ambiguous than in wild-type. c) DIC image overlaid 
with fluorescence from EGF-Alexafluor546. d) Representative track displacements in wild-type 
and Loa/Loa at 10 and 30 min chase. Loa/Loa tracks are shorter and displacement is slower 
than in wild-type. e) Retrograde velocity (positive values) is reduced in Loa/Loa at 10 and 30 
min chase. Anterograde velocity (negative values) is not significantly different across the 
genotypes.  
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All data analysed is from sample sizes of; n = 349 movements for wild-type from 
13 tracks (4 cells) and 419 movements from 15 tracks (5 cells), for Loa/Loa, at 
10 min. At 30 min; n = 232 movements for wild-type from 8 tracks (5 cells) and 
337 movements for Loa/Loa from 12 tracks (6 cells).     
Retrograde velocity was measured as positive movements towards the nucleus 
whereas anterograde velocity is represented as negative values. 
Initial observations identified a distinct lack of the fastest carriers, moving at 
velocities above 2 µms-1 in Loa/Loa, and 60% less moving at velocities above 1 
µms-1 at both time points) (Figure 3.2d-e).  
In both genotypes examined the majority of displacement occurred at speeds 
between 0 and 0.25 µms-1. This was not surprising as we, like others observed 
many endosomes ’rolling’ around for several seconds before longer movements 
were made [20,125]. For this reason these readings are more accurately a 
mixture of tiny retrograde, anterograde and side-wards steps than they are of 
distinct retrograde displacement.   
Analysis of dynein-dependent retrograde velocities highlighted a significant shift 
towards slower velocity in Loa/Loa at 10 and 30 min chase (P = 0.0025** at 10 
min and P = 0.0177* at 30 min) (Figure 3.2e). Table 3.1 shows the minimum, 
median and maximum retrograde velocities for both genotypes. At 10 min chase 
anterograde, stationary and retrograde movements were ~11%, ~13% and 
~77% respectively for wild-type and ~22%, ~15% and 63% for Loa/Loa, 
indicating a shift towards reduced retrograde movements and increased 
stationary pauses and anterograde movements in Loa/Loa. By 30 min chase 
the trend remained clear with anterograde, stationary and retrograde 
movements being ~10%, ~27% and ~63% respectively in wild-type and 18%, 
~25% and ~58% in Loa/Loa. Anterograde velocities were not significantly 
different across the time points or genotypes (Figure 3.2e). 
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 minimum median maximum 
wild-type 0.07 0.27 1.95 
Loa/Loa 0.07 0.21 1.95 
wild-type 0.07 0.23 3.16 
Loa/Loa 0.07 0.17 1.60 
 
Table 3.1: Minimum, median and maximum retrograde velocities in wild-type and Loa/Loa 
MEFs. 10 min (dark pink) and 30 min (pink) chase. Units = µms
-1
.  
To determine whether the altered dynamics of Loa/Loa velocities compared to 
wild-type was sufficient to affected overall displacement, I analysed all tracks 
(76% of total tracks measured) that remained in focus for at least 96% of 
frames. Displacement in Loa/Loa was significantly reduced when compared to 
wild-type at 10 min chase (P = 0.0020**). Track length ranged from 9.2 µm to 
15.8 µm (median 13.4 µm) in wild-type and 0.90 µm to 12.2 µm (median 4.4 
µm) in Loa/Loa. This trend remained at 30 min, with wild-type total displacement 
ranging from 5.1 µm to 42.3 µm (median 8.2 µm) and 2.2 µm to 9.2 µm (median 
5.3 µm) in Loa/Loa. The reduced displacement measurements in wild-type 
across the time points was found to be significantly different (P = 0.0442*) 
(Figure 3.3).     
 
Figure 3.3: Overall track length is reduced in Loa/Loa compared to wild-type. 10 and 30 min 
chase.  
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During analysis, movements were observed that were neither retrograde nor 
anterograde, but were distinct sideward movements relative to the directional 
movement to which the endosome was originally travelling.  ~5% of wild-type 
movements across both chase points were classed as side steps whereas in 
Loa/Loa the number was increased to ~7%.  When measuring the velocity and 
distance of these sideward movements it was found that in Loa/Loa the velocity 
was significantly slower (medians of 0.31 µms-1 and 0.17 µms-1 for wild-type 
and Loa/Loa respectively, P = 0.0003***) and movement was over shorter 
distances (0.90 µm and 0.42 µm for wild-type and Loa/Loa, respectively, P = 
0.0003***) (Figure 3.4 a-b). 
 
  
Figure 3.4: Altered side-stepping in Loa/Loa. a) Side stepping velocity is reduced in Loa/Loa 
compared to wild-type. b) Distance travelled during side stepping is reduced in Loa/Loa. For 
side stepping velocity and distance analysis, measurements from 10 min and 30 min chase 
were pooled together.  
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3.4 Live-cell tracking in motor neurons 
As dynein mutations have been linked to several neurological diseases, it was 
important to collect data from neuronal cells. Although both sensory and MN 
defects have been identified in the Loa mouse, I chose to examine the cellular 
processes within MNs, to advance the original work by Hafezparast et al; 2003, 
which identified an impairment in retrograde axonal transport in this cell type. A 
further consideration was the knowledge that the dynein mutations discussed in 
the introductory sections 1.2.2-1.2.5, highlight the dominant nature of dynein 
mutations in neurological disease. For this reason the use of +/Loa MNs were 
deemed to be more representative of human disease than Loa/Loa and were 
thus used for MN experiments. 
MNs were dissected at E13 and cultured to maturity for 1 week. MN status was 
determined by morphological comparison of MNs from the Loa mouse colony 
and those from a colony expressing green fluorescent protein (GFP) under the 
MN specific transcription factor, Homoeobox gene 9 (Hb9). Characteristics 
included; large cell bodies with several dendritic processes extending to form 
extensive branching patterns, and a single axon (Figure 3.5 a-b). Figure 3.5c 
shows light microscopy images of MNs cultured at day 1 and day 7, to 
demonstrate the extensive and elaborate branching patterns that are achieved 
by the time the MNs have matured. 
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Figure 3.5: Confirmation of MN cultures a) DIC image of a MN from the Loa colony, showing the 
same morphology as MNs expressing GFP under the Hb9 promoter (b). c) Light microscopy 
images of MNs at day 1 and day 7 in culture, showing the extensive branching that has 
occurred by day 7. d) MNs stained (green) for MAP2, Hb9 and Islet1 (Isl-1) in top, middle and 
lower panels respectively. Draq5 (red) stains DNA in the nucleus. 
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In addition, MNs were stained for Hb9, Islet1, which is expressed early in MN 
differentiation and MT associating protein 2 (MAP2), which is expressed 
predominantly in dendrites. Positive staining (green) was apparent for each 
(Figure 3.5d). 
Live-cell tracking in MNs was initiated following a 2-hour starvation period with a 
10 min simultaneous pulse of 5 ng/ml BDNF and 40 µg/ml of the pH- sensitive 
fluorescent dye pHrodo, linked to dextran. MNs were rinsed in media and 
replenishment with warmed MN starvation media for imaging (exact parameters 
can be found in section 2.5). pHrodo does not fluoresce in neutral pH of the 
media, however upon endocytosis into a more acidic environment the 
fluorophore becomes active and more intense as acidity increases. The 
simultaneous stimulation was deliberately used to increase the endosomal pool. 
Due to the non-specificity of pHrodo for RTKs however, the data collected is not 
solely representative of RTK transport, but of global retrograde transport in 
these cells. 
The range of velocities observed in MN tracking experiments were similar to 
those in the MEF cells, from -1.36 µms-1 (anterograde) to > 2 µms-1 (retrograde) 
and equally, there were fewer endosomes moving at speeds in excess of  
1µms-1 in +/Loa compared to wild-type at both 10 and 30 min chase (40% less 
at 10 min and 80% less at 30 min) (Figure 3.6b).  
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Figure 3.6: Transport is aberrant in +/Loa MNs. a) Kymographs of MN trafficking in wild-type 
and +/Loa MNs. b) Retrograde and anterograde velocities in wild-type and +/Loa.  d) Track 
displacement at 10 and 30 min chase. For each chase time analysed ‘n’ values were as follows; 
at 10 min, wild-type n = 257 movements from 8 tracks (5 cells) and n = 373 frame 
displacements from 8 tracks (7 cells) for +/Loa. At 30 min wild-type n = 194 movements from 7 
tracks (3 cells) and +/Loa n = 314 movements from 8 tracks (3 cells). 
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Retrograde velocities identified a trend for slower velocities in +/Loa at 10 min, 
which reached significance at 30 min chase (P = 0.0090**) Figure 3.6b and 
Table 3.2.  
 minimum median maximum 
wild-type 0.05 0.12 1.87 
Loa/Loa 0.05 0.12 1.37 
wild-type 0.05 0.12 1.57 
Loa/Loa 0.05 0.05 1.57 
 
Table 3.2: Minimum, median and maximum retrograde velocities in wild-type and +/Loa MNs. 10 
min (dark pink) and 30 min (pink) chase. Units = µms
-1
.  
Retrograde velocity decreased in +Loa between 10 and 30 min chase (P = 
<0.0001***), perhaps due to increased endosome size, producing an increased 
challenge to remain associated with mutant dynein and/or MTs (Figure 3.6b). 
Interestingly, although anterograde speed was not significantly different 
between the genotypes, there was an increased propensity towards 
anterograde movements in +/Loa compared to wild-type MNs, which had a 
distinct lack of such movements during the 30 min chase (Figure 3.6b). 
 Upper and lower ranges of track displacement in +/Loa compared to wild-type 
were distinctly different at 10 min (20.4 µm to 61.0 µm in wild-type and 4.2 µm 
to 55.4 µm in +/Loa) and at 30 min chase (14.1 µm to 42.2 µm for wild-type and 
7.6 µm to 33 µm for +/Loa) (Figure 3.6c). 
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3.5 Chapter 3 summary 
Data in this chapter has shown that the Loa mutation impairs retrograde velocity 
in two very different cell types. MEFs are more resilient in nature than MNs and 
it is likely that the susceptibility of MN to degeneration comes from the vast 
axonal distances that are difficult to overcome, hence the neurological 
phenotype observed. In the next chapter I have investigated the effect of the 
delayed GF-receptor transport on intracellular signalling. 
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Chapter 4 
Impaired retrograde trafficking affects cell signalling 
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4.1 Introduction 
Chapter 3 showed impaired transport of GFs and their receptors in Loa when 
compared to wild-type. Here, I will report the effect of delayed transport on ERK 
and JNK signalling. 
Endocytosis of receptor-ligand complexes creates a signalling endosome that 
can initiate signalling pathways until such time that the receptor-ligand complex 
is sorted for recycling or degradation. Due to the delayed transport in Loa, I 
hypothesised that, as a result, intracellular signalling would be prolonged in Loa. 
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4.2 Activation of ERK 1/2 is prolonged in Loa MEFs following EGF 
stimulation 
To investigate the effect of delayed endosome sorting and degradation on 
intracellular signalling, the ERK 1/2 pathway was explored. Wild-type and 
Loa/Loa MEFs were starved for 2 hours before stimulation with 20 ng/ml EGF. 
Cells were lysed to ensure disruption of all cellular sub-fractions at 10, 30, 60, 
120, and 180 min post application of the ligand. 
As shown in Figure 4.1, a peak of phosphorylated (active) ERK 1/2 (pERK 1/2) 
was apparent at 10 min post stimulation and, as expected [154] was transient 
such that by 60 min the wild-type levels were nearing those of the starved 
control. In contrast pERK 1/2 activation was found to be prolonged in Loa/Loa 
such that at 30 min post stimulation there was a 1.5 fold increase in pERK 1/2 
levels in Loa/Loa. At 60, 120, and 180 min the fold increases were 1.4, 1.2, and 
5.3, respectively, when compared to wild-type (Figure 4.1a-b).  
 
  
Figure 4.1: ERK 1/2 activation is prolonged in Loa MEFs. a) Following starvation, continuous 
stimulation with EGF produces a marked increase in pERK 1/2 activation, which is prolonged in 
Loa/Loa up to and including 180 min, n=3. b) Quantification of ERK 1/2 signalling in (a). 
 
It has been noted that at the 180 min time point, ERK 1/2 activation appears to 
be increasing in Loa/Loa. pERK 1/2 is known to translocate and cycle between 
the cytosol and nucleus [197] and thus it would be interesting to see if nuclear 
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translocation was affected in Loa, perhaps contributing to the elevated and 
apparent cyclic nature of pERK 1/2 in Loa. 
4.3 pERK 1/2 translocation is not affected in Loa 
To determine whether pERK 1/2 translocation was affected in Loa, subcellular 
fractions from wild-type and Loa/Loa MEFs were probed. For these experiments 
cells were subjected to a 10 min pulse of EGF prior to the chase periods of 10 
and 30 min.  A pulse was deemed to be most appropriate to distinguish 
between pERK 1/2 that was unable to translocate to the nucleus and that of 
either newly activated pERK 1/2 from continuous ligand stimulation or that 
which is cycling between the nucleus and cytoplasm.  
Increased pERK 1/2 levels in Loa/Loa were consistently observed in each of the 
sub-cellular fractions at 0 min chase (Figure 4.2a-b).  
 
 
Figure 4.2: pERK 1/2 nuclear translocation is not affected by Loa. a) pERK 1/2 levels in 
cytosolic (upper left), nuclear (upper right), membranous (lower left) and cytoskeletal (lower 
right) sub-cellular fractions isolated from MEFs. β-actin, XRCC1, calnexin and α-tubulin were 
used as loading controls for respective fractions. b) Graph shows quantifications of pERK 1/2 
levels in subcellular fractionations at 0 min chase (or 10 min stimulation), n=3. 
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Cytosolic, nuclear and membranous fractions, had 1.4, 8.2, and 1.7-fold 
increases in pERK 1/2 levels, respectively, compared to wild-type (Figure 4.2a-
b). Only one of three experiments had detectable p-ERK 1/2 in the cytoskeletal 
fractions, however this did show the same trend with a 2-fold increase in 
Loa/Loa compared to wild-type. 
To enable comparison of this result to that of the previous experiment (Figure 
4.1), it is important to recall that the current experiment is one of pulse-chase 
whereas the former is one of continuous stimulation. For this reason the 0 min 
chase time point would be reflective of 10 min in the previous experiment. A 
second and important difference is the method of sample collection. In the 
original experiment, sample collection was instantaneous at the time points 
indicated by application of a lysis buffer. In comparison, sub-cellular 
fractionation required many ice washing steps and incubation with several 
extraction buffers, taking ~60 min to complete. It is therefore likely that the 
increase in pERK 1/2 observed in Loa/Loa is actually a reflection of prolonged 
ERK 1/2 activation rather than an increase in response.  
It is tempting to conclude from the graph that the majority of p-ERK 1/2 is 
located in the nucleus following stimulation, this, although likely to be true, 
would be an assumption, for the following reason; the method used to collect 
sub-cellular fractions resulted in low protein concentrations that could not be 
measure by conventional means, I therefore loaded equal volumes for western 
blot analysis, regardless of the volume in which the sample had been collected. 
However, one would predict an increase in p-ERK in the nuclear fraction 
following EGF stimulation as, pERK 1/2 is known to locate to the nucleus to 
phosphorylate downstream effectors [197]. One would also predict a high level 
of p-ERK 1/2 in the cytosolic fraction due to the origin of activation. Also, 
activation occurs from membranous compartments, resulting in detectable 
levels there. It is therefore likely, that the trends in the graph are representative 
of the relative quantities of pERK 1/2 in the subcellular compartments. A 
conclusion that can be drawn from this data is that nuclear translocation of p-
ERK 1/2 is not affected as levels are increased across all fractions rather than, 
for example, the cytosolic fraction having an increase and the nuclear fraction a 
decrease in comparison to the wild-type. The lack of p-ERK 1/2 observed at the 
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later time point is likely due to low protein concentration in all samples due to 
limitations of the extraction technique and the return of p-ERK 1/2 levels 
towards baseline. 
4.4 pERK activation is not a result of starvation 
It was important to clarify that increased levels of pERK were not due to 
prolonged starvation, as ERK 1/2 is known to become active in response to 
starvation to induced autophagy in some cell types  for cell survival (reviewed in 
[175]. To test this, MEFs were starved for up to 4 hours and pERK 1/2 levels 
detected. pERK 1/2 was not detectable in the starved MEFs when compared to 
the un-starved control cells (Figure 4.3). 
 
 
Figure 4.3: Starvation does not activate ERK 1/2 in MEFs. pERK 1/2 is undetectable in 
comparison to un-starved controls.  
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4.5 Aberrant pERK 1/2 activation in motor neurons 
Following 2 hours starvation and subsequent stimulation with 5 ng/ml BDNF, 
whole cell, MN fractions were collected from wild-type and Loa heterozygotes 
(+/Loa) at 10, 30, 60, and 180 min post stimulation. 
pERK 1/2 levels were found to be similar between wild type and +/Loa in 
untreated cells (Figure 4.4). 
 
Figure 4.4: Starvation activates ERK 1/2 in Loa MNs. a) pERK 1/2 levels in +/Loa MNs are 
higher than wild-type following starvation. +/Loa does respond to BDNF activation but not to the 
same extent as wild-type, which has higher levels of pERK 1/2 at 10, 30 and 60 min post BDNF 
stimulation. b) Quantification of pERK 1/2 in (a). 
 
After 2 hours starvation pERK 1/2 levels in +/Loa are >2-fold higher than those 
of wild-type. As ERK 1/2 is known to induce autophagy for promotion of cell 
survival, increased levels of pERK 1/2 may indicate increased susceptibility of 
neurons to stress in +/Loa.  
Following BDNF stimulation, wild-type cells have a clear increase in pERK 1/2 
activity at 10 min, which, declines gradually over the course of time. However, 
levels are still >3-fold higher at 60 min than they were prior to stimulation. 
+/Loa responds to BDNF stimulation and follows the same trajectory as wild-
type over time, however, the overall amount is ~0.8-fold less than wild-type. At 
180 min wild-type pERK 1/2 levels drop below those of +/Loa, perhaps 
indicating prolongation of the signal in +/Loa after this point 
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4.6 p c-Fos levels are increased and prolonged in MEFs following EGF 
stimulation 
Having identified prolonged activation of ERK 1/2 in Loa/Loa MEFs attention 
was shifted to the effect this would have on the down-stream immediate early 
gene, c-Fos.  
Initial attempts to detect c-Fos revealed many bands on western blot and so it 
was essential to establish the identity of the bands. 
The predicted size of c-Fos is ~41 kDa, according to ExPASy, Bioinformatics 
Research Portal. A band of this size can be seen (Figure 4.5, lane 1), as can 
bands of ~49 KDa, ~62-65 KDa, and ~98 KDa. The ~49 KDa bands were 
predicted to be phosphorylated c-Fos (p c-Fos) and the ~98 KDa, p c-Fos/c-Jun 
dimers. However, the identity of the predominant bands at ~62-65 KDa, was not 
clear. 
 
Figure 4.5: Elucidation of c-Fos on western blot. Lanes 1-3 are lysates from MEFs stimulated 
with 20 ng/ml EGF, lanes 4 and 5 are motor neuron lysates stimulated with 5 ng/ml BDNF. 
Samples are treated with λ-protein phosphatase (λ-PP) or c-Fos blocking peptide as indicated 
to determine the identity of the bands.  c-Fos, p c-Fos, non-specific bands and c-Fos/c-Jun 
dimers were identified at 41 KDa, 49 KDa, 62-65 KDa and 98 KDa respectively. 
 
To confirm the predictions and reveal the identity of additional bands, whole cell 
lysates from MEFs simulated with 20 ng/ml EGF and lysed at 60 min post 
stimulation were treated with λ-protein phosphatase (λ-PP). Phosphatase 
inhibitors were omitted from the sample to be treated with λ-PP so as not to 
inhibit the phosphatase activity. 
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Following λ-PP treatment the ~98 kDa and ~49 kDa bands disappeared (Figure 
4.5, lane 2), confirming these bands as phosphorylated proteins. Due to their 
size and the antibody used I am confident that they are p c-Fos/c-Jun dimers 
and p c-fos respectively. The ~41 KDa band remained as expected for the 
unphosphorylated form of c-Fos. The intense bands ~62-65 KDa also remained, 
however a c-Fos blocking peptide showed these bands to be non-specific 
(Figure 4.5, lane 3). 
 A similar band pattern was observed in MNs but interestingly the non-specific 
doublet was not always present these samples (Figure 4.5, lane 4, 5), indicating 
detection of cell type specific proteins that are not c-Fos. 
Once the identities of the bands were determined, samples described in section 
4.1, which showed prolonged pERK 1/2 in Loa/Loa, were probed for c-Fos. 
My hypothesis was that prolonged activity of pERK 1/2 in Loa/Loa would result 
in an increase in c-Fos expression.  
There was 0.9-fold less c-Fos in Loa/Loa compared to wild-type following 
starvation (Figure 4.6a-b). However, following EGF stimulation c-Fos levels 
were increased in Loa/Loa by 1.5, 1.6, 1.6, 1.1 and 2.1-fold at 10, 30, 60, 120, 
and 180 min respectively (Figure 4.6a-b). 
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Figure 4.6: Levels of c-Fos and p c-Fos are increased in Loa MEFs. a) pERK 1/2, c-Fos and p 
c-Fos levels are increased and prolonged in Loa/Loa compared to wild-type. b) Quantification of 
c-Fos levels in Loa/Loa and wild-type. c) Loa/Loa p c-Fos peaks 60 min later than wild-type, at 
the120 min time point. pERK 1/2 is overlaid to show the relationship between the two, pERK 1/2 
declines before there is an increase in p c-Fos. d) Cell proliferation rates were the same in wild-
type and Loa/Loa. 
Levels of p c-Fos were, as expected, found to be low following starvation, 
however, although low in quantity there was ~4-fold less p c-fos in Loa/Loa than 
wild-type (Figure 4.6c).  
After stimulation with 20 ng/ml EGF a delay of around 30 min was observed, 
before the Ras/Raf/ERK pathway resulted in c-Fos translation and 
phosphorylation on Ser-362 and Ser-374. This can be observed between the 30 
and 60 min time points (Figure 4,6c). 
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The c-Fos phosphorylation curve in Loa/Loa was similar to wild-type until 60 
min. After which time wild-type levels of p c-Fos began to reduce back to basal 
levels whereas Loa/Loa p c-Fos levels continued to increase, peaking, higher 
than wild-type levels, at 120 min post EGF stimulation (Figure 4.6c). As EGF-
induced ERK 1/2 activation is transient, pERK 1/2 typically declines before 
additional c-Fos phosphorylation at Thr-325 and Thr-331 can occur. 
Phosphorylation at these latter two residues would produce 
hyperphosphorylated, stable p c-Fos which, would have greater impact on cell 
fate [154]. Due to prolonged activation of ERK 1/2 in Loa/Loa it would have 
been interesting to see if the hyperphosphorylated, stable c-Fos was present in 
Loa/Loa. Using size alone it was difficult to determine if there was a presence of 
hyperphosphorylated c-Fos. Attempts were made to detect 
hyperphosphorylated c-Fos using an antibody specific to phosphorylated Thr-
325 however, the antibody was inadequate to conclude either way (data not 
shown). 
It would be plausible to hypothesise that the altered levels of pERK 1/2 and p c-
Fos would result in increased proliferation rates in Loa/Loa. Surprisingly this 
was not found to be the case shown through regulated experiments (Figure 
4.6d). However, working with the cells over-time, left the impression that 
Loa/Loa MEFs proliferated at a slower rate than the wild-type, and that 
differences in proliferations rates between wild-type and Loa/Loa were highly 
dependent on the confluency of the cells. 
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4.7. p c-Fos and JNK are increased in Loa MNs following starvation 
Data in section 4.5 showed a 2-fold increase in pERK 1/2 levels in +/Loa 
compared to wild-type MNs following starvation and I suggested that this may 
initiate autophagy to promote cell survival. Following on from this finding it was 
important to determine if starvation-induced cell stress was sufficient to activate 
JNK. Similar to ERK1/2, following acute starvation, JNK can act as an activator 
of autophagy to promote cell survival.  If however, starvation is prolonged such 
that autophagic attempts to rescue the cell fail, the cell may enter class II 
programmed cell death, or autophagy-induced cell death pathway. Entry into 
apoptosis has been shown to be preceded by heightened, sustained levels of c-
Fos (see sections 1.5.1-1.5.3).  
Marked JNK activation was found in +/Loa following starvation, which declined 
with time following BDNF stimulation (Figure 4.7a-b). Wild-type did not show a 
distinct activation but did fluctuate between the 10 min and 60 min time points.  
 
 
Figure 4.7: JNK and p c-Fos is activated in Loa MNs following starvation.  a) A peak of JNK 
activity is observed following starvation in +/Loa MNs, which, declines following BDNF 
stimulation. p c-Fos is dramatically induced by starvation in +/Loa MNs whereas a gradual 
incline is apparent in wild-type following starvation and subsequent stimulation with BDNF. b) 
Quantification of p c-Fos and JNK in (a) 
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When looking at c-Fos expression, starvation increased c-Fos in both 
genotypes however, +/Loa levels were 2-fold higher than those of wild-type, 
following the pattern seen with JNK (Figure 4.7a-b). c-Fos levels, like JNK 
reduced by 30 min post stimulation to a level that was maintained until the end 
of the experiment. In contrast wild-type MNs had a gradual increase in c-Fos 
levels over the course of time, following a pattern expected from pERK 1/2 
activation (Figure 4.4a-b and 4.7a-b). 
4.8 Chapter 4 summary 
EGF stimulation of MEF cells highlighted prolonged activation of ERK 1/2, 
which in turn resulted in increased levels of both c-Fos and active p c-Fos in 
Loa/Loa when compared to wild-type. Starvation did not appear to play a 
significant role in these signalling events. In contrast, starvation in MNs 
activated ERK 1/2, JNK and c-Fos in +/Loa to a much greater extent than wild-
type. It is plausible that Loa inflicts increased susceptibility to stressors such as 
nutrient deprivation and as a result pERK and JNK are activated at a faster rate 
and to a greater extent than in healthy, wild-type cells. The purpose of which 
may be to induce autophagy and promote cell survival. If autophagic processing 
is hindered due to Loa the cell may be pushed towards cells death. 
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Chapter 5 
Differential expression of TCF25 and KLC1 in Loa 
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5.1 Introduction  
Chapter 3 and 4 demonstrate how Loa affects dynein processivity, which in turn 
leads to alterations in cell signalling. This current chapter arose from a 
prediction of multiple differentially expressed genes in Loa, and has resulted in 
some interesting findings, particularly with regards to transcription factor 25 
(Tcf25) and kinesin light chain 1 (Klc1). 
5.2 TCF25 is up-regulated during Loa brain development 
Microarray analysis was carried out by Dr Marcel van der Brug, Department of 
Neuroscience, Scripps Research Institute, Jupiter, Florida 33458. Briefly, RNA 
was collected from two wild-type, +/Loa and Loa/Loa E13 mouse brains using a 
trizol-based protocol, (and by Dr Violeta Soura). Illumina mouse oligonucleotide 
arrays (Mouse-6_V1) and Illumina Beadstudio software suite were used to 
determine differential expression. Reproducibility across the samples was good 
to excellent among the majority, as confirmed by their ‘diff’ scores [82]. Of the 
94 genes identified as being differentially expressed in Loa/Loa compared to 
wild-type, 79 were up-regulated whilst 15 were down-regulated. Comparisons 
between +/Loa vs wild-type, and +/Loa vs Loa/Loa were also made. A full list of 
genes, expression values and Diff. scores can be found in the appendix. There 
were two genes identified as being of particular interest due to their relationship 
with dynein and the signalling pathways discussed in chapter 4. They are the 
genes encoding TCF25 and KLC1, which were shown to have a Loa, dose 
dependent up or down regulation respectively (Table 5.1). 
Gene wild-type 
average signal 
 +/Loa average 
signal 
Loa/Loa average 
signal 
Tcf25 
 
747.0996 
 
1063.559 
 
1172.774 
 
Klc1 
 
7438.797 
 
6275.124 
 
2454.743 
 
 
Table 5.1: Klc1 and Tcf25 are differentially expressed in Loa.  Microarray analysis indicates up-
regulation (green) and down-regulation (purple) in +/Loa and Loa/Loa, respectively, compared 
to wild-type. n=2. 
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To confirm the microarray data, mRNA was extracted from 3 wild-type, +/Loa 
and Loa/Loa E13 brains. Reverse transcription reactions produced cDNA to be 
used for quantitative real-time polymerase chain reaction (qPCR) analysis. 
qPCR did not revealed a significant difference between expression of Tcf25 in 
+/Loa compared to wild-type (triplicate, mean cycle thresholds (CT) were 24.26 
and 23.41, respectively) , however there was a 1.5 and 1.7-fold up-regulation of 
Tcf25 in Loa/Loa (CT = 22.82), compared to wild-type and +/Loa respectively (P 
= 0.0006*** and P = 0.0018**, respectively, according to a Mann-Whitney U test 
of significance) (Figure 5.1a-b).  
 
 
Figure 5.1: Tcf25 and Klc1 are up-regulated in Loa. a) TCF25 is up-regulated in Loa/Loa 
compared to +/Loa and wild-type, as determined by qPCR. b) Graph shows quantification of the 
data in (a). c) Kinesin light chain 1 is up-regulated in +/Loa and Loa/Loa compared to wild-type, 
and in Loa/Loa compared to +/Loa. d) Graph shows quantification of the data in (c). n = 3 E13 
brains from each genotype, repeated in triplicate. NTC = no template control. 
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Interestingly, quantification of KLC1 revealed differences to that of the 
microarray data. Compared to wild-type Klc1 was found to be 1.5-fold up-
regulated in +/Loa (CTs were 27.6 and 27.2 for wild-type and +/Loa respectively 
and P = 0.0061**) and 3.1-fold up-regulated in Loa/Loa (CT = 26.22) compared 
to wild-type (P = <0.0001***). The difference between +/Loa and Loa/Loa was 
also significantly different at 2.1-fold increase (P = 0.0003***) (Figure 5.1c-d). 
These findings were interesting both from the relevance of the genes involved 
but also due to the discrepancies between the different techniques used. To 
address this and to identify whether an increase in messenger RNA actually 
translated to an increase in protein expression, protein from E13 brains was 
extracted for western blot analysis. Each gene will be discussed separately, 
along with subsequent experimental findings, beginning with Tcf25. 
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5.3 TCF25 protein expression is altered in E13 Loa brains and MEF cells 
Western blot analysis confirmed the significant up-regulation of TCF25 in 
Loa/Loa compared to wild-type, by 2.8-fold (Figure 5.2a) (P = 0.0317*, Mann-
Whitney U), confirming both the microarray and qRT-PCR data (Figure 5.1a-b, 
Table 5.1). TCF25 has 5 known isoforms, four between 68-72 kDa and one 
larger isoform at ~77 kDa. Two distinct bands can be seen on western blot and 
the expression difference between the genotypes is significant only in the 
smaller of the isoforms (P = 0.0159*, Mann-Whitney U) (Figure 5.2a-b).  
 
 
Figure 5.2: TCF25 protein expression is up-regulated in Loa E13 brains. a) Western blot 
showing the 68-72 kDa (lower band) and ~77 kDa (upper band) isoforms of TCF25. The smaller 
isoforms are significantly up-regulated in Loa/Loa compared to wild-type. b) Quantification of the 
data in (a) showing that TCF25 up-regulation is specific to the smaller, 68-72kDa TCF25 
isoforms, n = 3. 
 
TCF25 controls the transcription of  c-Fos by regulating the expression of 
SRF(see section 1.4.6). Due to the observed alteration in ERK 1/2 and c-Fos 
expression in MEFs (chapter 4), it would be interesting to explore any 
alterations of TCF25  in MEFs. Thus, cells were starved for 2 hours and then 
pulsed for 10 min with 20 ng/ml EGF. Whole cell lysates were collected for 
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detection of TCF25 and untreated/un-starved cells were used as a negative 
control. 
There was a distinct lack of the ~77 kDa isoform in all of the Loa/Loa samples, 
which was significantly different from 0 min to 120 min post EGF stimulation (P 
= 0.0134* according to two-way ANOVA) (Figure 5.3 a-d).  
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Figure 5.3: TCF25 expression is aberrant in Loa MEFs. a) Large, ~77 kDa isoforms of TCF25 
are lacking in Loa/Loa MEFs. b) Quantification of total TCF25 revealed a reduction in Loa/Loa 
compared to wild-type. This reduction was not due to significant changes in the smaller, 88-72 
kDa isoforms (c), but was specific to the larger ~77 kDa isoforms (d). n = 3. 
 
EGF stimulation increased the expression of the smaller isoforms of TCF25 in 
both genotypes at 0 min chase, however, there was a 1.4-fold increase in 
Loa/Loa expression compared to wild-type (Figure 5.3c). 
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5.4 KLC1 protein expression is up-regulated in Loa 
Microarray data revealed down-regulation of KLC1 in Loa/Loa when compared 
to wild-type. In contrast qRT-PCR showed a significant up-regulation. As kinesin 
is the opposing motor to dynein, KLC1 was of great interest even though there 
were some discrepancies in the data. Thus, I decided to check whether 
increased mRNA translated to an increase in protein levels. Western blot 
analysis revealed a 1.4 and 1.3-fold increase in KLC1 expression in +/Loa and 
Loa/Loa respectively, compared to wild-type (Figure 5.4a-b). 
 
 
Figure 5.4: KLC1 protein expression is increased in Loa MEFs.  a) KLC1 protein levels are 
increased in +/Loa and Loa/Loa when compared to wild-type. b) Graph showing quantification of 
the western blots, n = 3. 
 
KLC1 has been shown to have a regulatory effect on KHC by holding it in a 
closed and inactive conformation, unbound from MTs. Upon cargo binding it is 
suggested that the conformation of the kinesin complex alters, to be in a more 
open complex for binding and transport along MTs (see Figure 1.5). For this 
reason it would be interesting to determine if the elevated levels of KLC1 in Loa 
were present in the soluble or MT-bound fraction of the cell. To test this, a MT 
pull-down assay was performed by Dr Wenhan Deng, University of Sussex, 
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followed by western blot analysis of MT-bound KLC1. Briefly, newborn mouse 
brains were homogenised, followed by high-speed centrifugation and recovery 
of cytosolic supernatants. Taxol and adenylyl-imidodiphosphate (AMP-PNP) 
were added to stabilise MTs and bind kinesin respectively before separation of 
MT-bound proteins and soluble fractions by further centrifugation [82]. I then 
proceeded with western blot analysis of the MT-bound and soluble fractions. 
There was a 70% increase of KLC1 in the supernatant of Loa/Loa when 
compared to wild-type (Figure 5.5a-b) and a 50% reduction in that bound to 
MTs (Figure 5.5c-d), which reached significance according to a Mann-Whitney 
U test of significant (P = 0.0294*).  
 
Figure 5.5: Soluble KLC1 is increased in Loa while there is less KLC1 bound to MTs. a) Loa/Loa 
has more KLC1 in the supernatant than wild-type following a microtubule (MT) pull-down assay. 
b) Quantification of the data in (a). c) Loa/Loa has less KLC1 associated with MTs than wild-
type. d) Quantificaition of the data in (c), P = 0.0294*. 
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Dynein is a known cargo of kinesin. For this reason DIC was used for immuno-
precipitation to identify whether there were alterations in dynein-kinesin 
association. KLC1 was found to associate with DIC 6.8-fold more strongly in 
Loa/Loa than in wild-type brain samples (Figure 5.6a-b). 
 
 
Figure 5.6: KLC1 associates more strongly with DIC in Loa. a) Immunoprecipitation of the 
dynein complex with the 74.1 antibody to DIC revealed and increased association of KLC1 with 
DIC in Loa/Loa compared to wild-type. Washing the sepharose beads  with detergent (bottom 
right panel) eliminated the non-specific binding KLC-1 to the beads in the IP-IgG negative 
controls, which was apparent in the non-detergent washes (bottom left panel). b) Quantification 
of the western blots revealed a 6.8-fold increase in association between KLC1 and DIC in 
Loa/Loa compared to wild-type. 
 
5.5 Chapter 5 summary 
Chapter 5 has identified aberrant expression of TCF25 and KLC1 in Loa. 
Altered regulation of specific TCF25 isoforms may identify compensatory 
pathways to rescue impaired cell development in neurons.  
Up-regulation of KLC1 provokes an interesting model of dynein-kinesin, motor-
cooperation, which will be discussed further in chapter 6, but is likely an attempt 
to restore homeostasis within the cell.   
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Chapter 6 
Discussion 
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6.1 Introduction 
Throughout this thesis significant changes have been identified as 
consequences of a single point mutation (Loa) in Dync1h1. These changes are 
not cell-type specific in their origin but are more so in their response. As an 
example, chapter 3 identified aberrant but comparable, intracellular trafficking in 
both MEF cells and MNs. Both cell types showed reduced retrograde speeds 
and increased numbers of anterograde movements in Loa, however, it was 
chapter 4 and 5 that began to show how the cell types differ in their responses 
through intracellular signalling pathways. There are some findings from each of 
the results chapters (3-5) that I would like to discuss in further detail. 
6.2 Dynein kinetics 
Chapter 3 (Figure 3.1a-b) identifies an increased number of EGF-containing 
vesicles in Loa/Loa compared to wild-type across the time course and with 
greatest significance at 10 min chase. This is the time during which EEs fuse 
together for sorting in the emerging MVB. The increased number of particles 
remaining in Loa/Loa at this time may be representative of altered EE 
morphology and delayed MVB formation. This observation is intriguing due to 
previous work in our lab that showed an increased affinity between DHC, DIC 
and DLIC, and a reduced affinity for the p150 subunit of dynactin, in Loa [82]. 
As DIC, DLIC and dynactin are regulators of cargo attachment, this finding may 
be indicative of impaired cargo docking to the dynein complex, delaying 
subsequent transport along MTs. At later timepoints an increased number of 
EGF-containing vesicles remain in Loa/Loa compared to wild-type. This may 
indicate delayed degradation of EGFR at this point. 
Live cell imaging of EGF-Alexafluor546 identified a couple of interesting 
findings. The first was the increased number but reduced speed and distance of 
side-steps made in Loa compared to wild-type. Dynein is known to make side-
steps, probably from one MT to another to enable navigation through a crowded 
cytoplasm. The movements observed in Loa/Loa however, may not be 
representative of an energy-dependent ‘step’, rather, they may indicate that the 
dynein complex is either dissociating from MTs [20], or, as suggested from our 
previous work [82] from the cargo it is carrying.  
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Dynein processivity is reliant on co-operation between dynein heads (see 
section 1.1.5). Due to the location of Loa in the homodimerisation domain of the 
two heavy chains, Loa may alter the force applied to both the leading and 
lagging heads, resulting in increased bidirectional movement. Multiple motors 
are required for cargo transport and it is possible that reductions in dynein-MT 
[20] and/or dynein-cargo associations [82] brought about by Loa would result in 
reduced numbers of full-functional dynein complexes associated simultaneously 
with both cargo and MTs for transport to occur, thus resulting in the aberrant 
track velocities and premature run terminations observed [20, 199, 200]. 
In addition cooperation between the two motors has been well established [23] 
however inhibition of one motor does not necessarily result in inhibition of the 
other [201]. It is therefore plausible that, in Loa, any tug-of-war between kinesin 
and mutant dynein is balanced more favourably towards the anterograde 
movement of kinesin than it is towards the dynein mediated retrograde 
movement.  
6.3 Loa influences on cell signalling 
Chapter 4 demonstrates well the difference in activation between EGF and 
BDNF. The former activates the transient Ras/Raf pathway, whilst the latter 
incorporates the Rap1 pathway for sustained activation (section 1.4.3 and 1.4.4, 
and Figure 4.1 and 4.4).  
In MEF cells Loa induced prolonged ERK 1/2 activation. Moreover, activation of 
the IEG c-Fos was increased. As consequence of this, it would be reasonable 
for one to predict that cell proliferation would be increased in Loa/Loa cells 
compared to wild-type however, interestingly no statistical difference in cell 
proliferation was found between Loa/Loa and wild-type (Figure 4.6d). An 
explanation for this may lie in evidence that a constitutively active Ras/Raf/ERK 
1/2 pathway is sufficient for a cell to enter senescence or even apoptosis 
(reviewed in [198]). Although not investigated here, the study of senescence 
and/or apoptosis in Loa MEFs would be interesting work for the future. 
In MNs pERK 1/2 levels were reduced compared to wild-type following GF 
stimulation. This difference may be due to the prior response of MNs to 
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starvation. It would be informative to repeat the GF stimulation on MNs that are 
not already in a stressed state as I would predict a similar response to that of 
the MEF cells. If my hypotheses were correct, prolonged activation of ERK 1/2 
and increased levels of c-Fos, may, in a terminally differentiated cell such as a 
MN, stress the cell to such an extent that it is pushed into programmed cell 
death. 
ERK 1/2 and JNK can both initiate autophagy to promote cell survival during 
nutrient deprivation. Since autophagy is dependent on dynein transport, 
impairment of autophagosome transport that mirrors endosome transport in Loa 
may result in a stalling of autophagosomes in the cytosol, rendering the 
neuroprotective aspect of this pathway redundant. The stress of prolonged 
starvation, coupled to impaired autophagosome processing for nutrient 
recycling would likely switch the JNK signal from one of protector to one of class 
II, autophagy- induced cell death, as the volume of the stalled autophagosomes 
overtakes the volume of the cytosol. In support of this theory is the previously 
reported increase in accumulation of autophagosomes in Loa [196] and the 
observed ERK 1/2 and JNK elevation compared to wild-type following 2 hours 
starvation (Figure 4.4a-b and 4.7a-b).  Furthermore, the peak in c-Fos activation 
observed in +/Loa MNs following starvation is consistent with activation via JNK 
as opposed to ERK 1/2 and entry into apoptosis (Figure 4.7) [187].  
In my experiments GF stimulation after 2 hours starvation coincided with a 
decrease in JNK levels and an increased pERK 1/2. This may indicate that GFs 
have the ability to salvage the cell from its autophagy-induced apoptotic fate. 
However the patterns observed following starvation and previous evidence that 
JNK is the overriding factor to ERK 1/2 [203] is more suggestive that apoptosis 
has been initiated. Cell survival assays and the use of autophagic and apoptotic 
markers would help to determine the mechanisms and pathways leading to cell 
fate. Signalling effects in MNs and MEFs are summarised in Figure 6.1. 
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Figure 6.1 Summary of signalling in Loa MNs and MEFs. Loa results in aberrant transport 
kinetics, which influence cell-type specific responses. +/Loa MNs appear to be more susceptible 
to starvation, indicated by increased pERK 1/2, p c-Fos and JNK following a 2 hour starvation 
period. This is perhaps due to delayed processing of autophagosomes and will push the cell 
towards cell death.  In contrast starvation does not initiate these signals in MEFs. GF 
stimulation in MEFs results in prolonged pERK 1/2, and increased levels of c-Fos. This is not 
reflected by an increase in cell proliferation and thus may be indicative of entry into senescence. 
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6.4 TCF25 identified as a potential biomarker of disease 
The up-regulation of TCF25 identified in E13 Loa/Loa brains (Table 5.1, Figure 
5.1a-b, and 5.2a-b) is an interesting finding for two reasons: TCF25 is 
expressed intensely in developing DRGs and to a lesser but significant extent, 
in the adult brain [165]. It is therefore possible that up-regulation of TCF25 in 
Loa/Loa may be indicative of an attempt to compensate for impaired neuronal 
migration and developmental morphology, identified in Loa (see section 1.2.10). 
Due to the minimal knowledge surrounding TCF25 in any pathway other than 
that of SRF regulation, these mechanisms would need to be elucidated through 
further work.  
Alternatively, there are reports that overexpression of isoform b (71 kDa) is 
linked to an increase in cell death [202]. As the 68-72 kDa isoforms were 
prominent in Loa/Loa E13 embryos, it would be useful to identify which of the 
68-72 kDa isoforms are up-regulated as they may reveal novel protein functions 
and may produce a useful biomarker of neurological disease, potentially for 
diseases such as SMA-LED, which, in some cases harbours a mutation just 2 
nucleotides away from Loa and thus potentially may show the same alteration in 
gene expression (see section 1.2.4). 
Loa/Loa MEFs revealed the absence of the ~77 kDa TCF25 isoform (Figure 
5.3a-d), which is interesting because in humans the ~77 kDa isoform of 
nulp/TCF25 has been shown to be a negative regulator of SRF [164]. The data 
presented here is therefore suggestive that the distinctive lack of the ~77 kDa in 
Loa/Loa MEFs may, render the cell unable to regulate aberrant activation of 
ERK 1/2 through this pathway (Figure 4.1a-b) and therefore an increase in c-
Fos is observed (Figure 4.6a-c).  
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6.5 Cooperation between motors to restore homeostasis 
Impaired retrograde kinetics in Loa, likely leads to an increase in dynein at the 
plus end of MTs, along with an imbalance of cargo and organelle positioning 
within the cell. Up-regulation of KLC1 (Figure 5.1c-d and 5.4a-b) may be a 
compensatory mechanism to hold KHC inactive, thus inhibiting further plus-end 
transport of cargos. Data from the MT-binding assays support this theory as 
more soluble KLC1 is present in Loa/Loa brain homogenate compared to wild-
type (Figure 5.5a-b), and there is more KLC1 bound to MTs in wild-type (Figure 
5.5c-d). KLC1 isoforms have been shown to determine specificity for cargos, 
and dynein has been shown to interact with KLC1, through DIC [204, 205]. 
Immunoprecipitation revealed a greater association of KLC1 with DIC in 
Loa/Loa compared to wild-type (Figure 5.6). Thus, at the local level in Loa, 
detection of reduced retrograde transport may signal for the cell to send more 
dynein to the cell periphery in preparation of retrograde transport. The 
interaction between KLC1 and DIC would enable kinesin complex activation for 
this to occur. A wider regulatory mechanism may prevent the anterograde 
transport of further cargo to the cell periphery to try and restore the global 
balance across the cell as a whole (Figure 6.2). 
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Figure 6.2: Model of KLC1’s role in regulation of cargo transport in the dynein deficient Loa 
mouse. a) Global effect of increased KLC-1 in Loa/Loa cells. Retrograde transport of cargos via 
dynein is slow. An imbalance of organelles, neurotrophic factors and motor proteins is detected 
by the cell. The cell responds by increasing KLC-1 expression, which holds kinesin inactive, 
preventing further transport of cargos to the periphery of the cell. b) Local effect of increased 
KLC-1 in Loa/Loa cells. KLC-1 binds to more DIC in Loa/Loa cells than wild-type. Binding 
activates kinesin to transport dynein and other cargos to the periphery of the cell. Preferential 
transport of dynein and a reduction in transport of other cargoes will increase the quantity of 
available dynein motors for retrograde trafficking.  
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6.6 Conclusion 
The data presented in this thesis demonstrate kinetics of dynein mediated 
transport in both MEF cells and MNs. Comparisons of wild-type cells and those 
expressing mutant dynein (Loa) have produced intriguing results with regard to 
direct effects on kinetics and indirect effects on cell signalling and gene 
expression. These data have advanced our understanding of dynein’s role in 
endocytic trafficking and signalling and may help us to establish causal 
pathways leading to neurodegeneration and neuropathies. Through 
understanding comes advancement towards therapeutic targets for reduction 
and/or elimination of the severe physical and mental phenotypes associated 
with such diseases. This work has identified TCF25 as one such possibility and 
GF induced increases in cell signalling are suggestive that GF antagonists may 
be another.  
The lack of resilience in neuronal cells likely comes from the intrinsic post-
mitotic nature and immense size of these remarkable cells. Finding a cure for 
neurological diseases is arguably the greatest challenge facing the scientific 
world today, however I hope that data provided here is a step in the right 
direction. 
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Appendix 
 
Section 1: wild-
type v Loa/Loa 
Gene wild-type +/Loa Loa/Loa Difference rank DiffScore rank 
1110033K02Rik 299.7043 446.701 490.4942 190.7899 117 15.2402 88 
1700001C14Rik 606.3853 835.638 1036.026 429.6407 63 336.687 1 
2310021P13Rik 3056.875 4235.99 4646.516 1589.641 12 13.9501 92 
3110037B15Rik 734.1217 989.026 1169.834 435.7123 62 50.0171 37 
4731420N21 811.3674 1139.31 1256.109 444.7416 59 58.437 30 
4833414E09Rik 1326.167 1912.92 2255.813 929.646 23 32.0577 56 
4930453J04Rik 520.0317 825.538 931.2266 411.1949 66 69.7107 23 
5330432J10Rik 480.5189 664.47 843.3755 362.8566 78 53.0645 33 
5830407P18Rik 399.3127 608.566 664.9161 265.6034 95 68.6584 24 
5830417I10Rik 767.9138 1094.19 1214.533 446.6192 58 59.2835 27 
6030432P03Rik 1113.585 1504.99 1678.134 564.549 44 34.6564 50 
6720454L07Rik 309.5771 429.248 483.2011 173.624 123 21.4227 72 
8430401P03Rik 440.2191 594.196 681.1563 240.9372 107 51.2713 34 
9430047F21Rik 440.1024 632.859 694.6588 254.5564 100 59.2835 27 
9530014D17Rik 744.2233 1068.31 1126.951 382.7277 72 20.901 75 
9530018D06Rik 360.5136 621.356 651.3539 290.8403 89 32.4838 54 
9630013P03Rik 1006.005 1163.71 1551.673 545.668 46 13.3467 93 
9630032J03Rik 663.9113 917.229 1041.446 377.5347 75 26.4065 64 
9830166E18Rik 496.7465 723.582 822.1331 325.3866 84 74.0551 20 
9845300_4289 1225.763 895.876 740.4278 -485.335 55 -73.441 21 
A130017C09Rik 337.4109 514.532 602.6982 265.2873 94 32.4838 54 
A430103B12Rik 783.9323 1299.09 1520.167 736.2347 34 115.288 12 
A530083M17Rik 709.1996 957.445 1237.907 528.7074 49 49.9902 38 
A630076E03Rik 599.74 897.883 976.7273 376.9873 76 26.4065 64 
A730021C13Rik 673.0079 864.588 1169.08 496.0721 53 17.7985 77 
A730058G16Rik 316.0765 443.98 482.7279 166.6514 126 21.2349 73 
A830029A02Rik 386.3829 596.629 636.8015 250.4186 102 28.6847 58 
A930004J17Rik 590.6741 782.98 950.929 360.2549 79 94.8222 18 
A930019L04Rik 486.7676 781.841 750.7315 263.9639 96 27.7802 61 
A930104B17Rik 292.7176 355.415 471.2229 178.5053 121 26.5706 63 
Acat3 2819.561 2333.98 1691.049 -1128.51 20 -17.084 79 
Acvr1b 1959.145 1400.95 1175.916 -783.229 30 -125.15 10 
AI605517 756.8443 1011.03 1160.179 403.3347 69 34.4666 51 
Ankrd11 749.5829 1076.73 1249.005 499.4221 51 25.3871 67 
Atp6ap2 1632.037 1369.61 1054.399 -577.638 41 -17.672 78 
B130020M22Rik 607.6091 1013.71 1179.1 571.4909 43 336.687 1 
B130047N10Rik 315.5312 495.975 485.5807 170.0495 124 26.7048 62 
B230208H17Rik 708.1891 1080.04 1072.018 363.8289 77 90.1765 19 
C130002K18Rik 354.4715 461.704 623.4166 268.9451 92 43.8329 42 
C130045F17Rik 353.6219 537.828 608.0193 254.3974 101 23.868 70 
C130064E22Rik 471.4221 631.384 720.0695 248.6474 104 21.1806 74 
C330006D17Rik 351.4017 485.573 543.8321 192.4304 116 24.2849 69 
C530036F05Rik 964.4423 1335.62 1564.357 599.9147 37 24.9076 68 
C530040B18Rik 384.4811 529.288 581.4246 196.9435 114 16.5209 81 
C79267 388.7869 637.239 638.6948 249.9079 103 55.6839 32 
Chd1 312.8964 450.732 502.9508 190.0544 118 15.6768 83 
Clasp1 786.2283 1176.6 1247.348 461.1197 57 336.687 1 
Clspn 352.4508 472.391 608.5924 256.1416 99 26.2175 66 
Csnk1e 5784.711 5941.49 8724.002 2939.291 6 23.4589 71 
D030064C08Rik 493.6785 683.019 834.3757 340.6972 81 57.474 31 
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D230005E09Rik 359.535 531.947 626.7526 267.2176 93 47.8395 39 
D230017C05Rik 1527.57 1886.89 2437.518 909.948 26 69.8255 22 
D230034L24Rik 730.958 1004.9 1169.044 438.086 61 336.687 1 
D430007A19Rik 1805.916 2353 2910.541 1104.625 21 44.1363 41 
D930044I17Rik 503.8788 739.279 911.0601 407.1813 67 111.609 13 
E130318A13Rik 207.0589 271.215 361.6896 154.6307 128 16.7565 80 
E430033B07Rik 955.5 1134.48 1722.673 767.173 31 110.428 14 
EG633692 2088.418 1671.67 1343.883 -744.535 32 -13.006 94 
Eif2s3y 165.0472 517.901 800.116 635.0688 36 20.2864 76 
Enah 564.2087 732.42 1007.616 443.4073 60 29.0874 57 
Golga2 764.8349 1101.29 1568.636 803.8011 29 336.687 1 
Gtl2 695.7593 1017.66 1233.999 538.2397 47 15.6065 84 
Gukmi1 409.3028 620.794 625.0294 215.7266 110 36.7335 48 
Jarid1d 160.5449 308.627 396.0511 235.5062 108 41.0403 43 
Jph4 344.2819 441.828 521.3304 177.0485 122 28.0761 60 
Klc1 7438.797 6275.12 2454.743 -4984.05 3 -45.904 40 
LOC100039786 4105.797 3393.41 2602.609 -1503.19 13 -28.43 59 
LOC100045054 502.2799 807.898 883.488 381.2081 73 16.2594 82 
LOC100046744 2319.667 3180.27 4433.915 2114.248 11 14.9726 89 
LOC100047082 1916.344 2476.57 3136.012 1219.668 17 67.5043 25 
LOC386124 584.102 710.671 924.6829 340.5809 82 14.4001 91 
LOC641366 430.9122 776.694 678.3563 247.4441 106 35.7454 49 
Mtap2 519.0618 893.484 919.5319 400.4701 70 62.6883 26 
Mtch2 6759.886 5602.26 4458.917 -2300.97 10 -121.16 11 
Nipbl 2230.627 3141.73 3437.668 1207.041 18 39.7463 45 
Nrk 765.6023 1346.22 1264.095 498.4927 52 336.687 1 
Nsmce2 3368.11 2652.1 2224.824 -1143.29 19 -40.548 44 
Pcmt1 1998.705 1639.68 1257.261 -741.444 33 -15.463 85 
Ppp1r12a 1170.69 1517.88 2446.846 1276.156 15 336.687 1 
Ppp1r13b 1347.261 1032.68 791.0375 -556.224 45 -37.863 47 
Prdm2 1662.745 2198.37 2547.745 885 28 59.2835 27 
Psmd5 1557.549 1187.63 1024.593 -532.956 48 -106.57 16 
Purb 711.3504 972.354 1134.929 423.5786 65 33.3361 52 
Rrm2 895.1329 603.57 515.8557 -379.277 74 -14.971 89 
scl0001487.1_50 1318.808 1231.8 837.1353 -481.673 56 -50.914 36 
scl000972.1_0 456.4228 715.201 794.9742 338.5514 83 108.35 15 
Slit2 340.4627 477.252 511.2849 170.8222 125 15.4202 87 
Stxbp3 269.1633 367.459 422.5476 153.3843 129 15.4222 86 
Tcf25 747.0996 1063.56 1172.774 425.6744 64 99.3109 17 
Tmem63b 2207.706 2985 3446.837 1239.131 16 50.9301 35 
Tssc8 738.8944 1131.16 1313.397 574.5026 42 33.0558 53 
Ttn 471.2359 773.904 959.9691 488.7332 54 336.687 1 
Xist 3145.592 3236.25 292.1439 -2853.45 7 -334.19 9 
Zfp326 538.4688 793.265 817.4946 279.0258 91 38.4322 46 
 
 
Section 2:  
wild-type v 
+/Loa           
 
  
4930453J04Rik 520.0317 825.538 931.2266 305.5064 86 69.7107 6 
5830407P18Rik 399.3127 608.566 664.9161 209.2537 112 68.6584 7 
9530018D06Rik 360.5136 621.356 651.3539 260.8425 97 32.4838 11 
A430103B12Rik 783.9323 1299.09 1520.167 515.1567 50 115.288 4 
A930019L04Rik 486.7676 781.841 750.7315 295.0736 88 27.7802 12 
Adam33 372.1302 596.789 533.3846 224.6584 109 10.9142 20 
107 
 
B130020M22Rik 607.6091 1013.71 1179.1 406.0979 68 336.687 1 
B130047N10Rik 315.5312 495.975 485.5807 180.4441 120 26.7048 13 
Bst2 1777.211 1184.26 1479.183 -592.952 38 ####### 24 
C130045F17Rik 353.6219 537.828 608.0193 184.2058 119 23.868 14 
C230048N02Rik 273.0325 434.837 297.3929 161.8042 127 ####### 24 
C79267 388.7869 637.239 638.6948 248.4521 105 55.6839 9 
D430006A07Rik 349.3383 545.037 520.7577 195.6987 115 16.1778 17 
Ddx6 1553.528 2469.47 2642.629 915.941 25 2.44077 22 
Gukmi1 409.3028 620.794 625.0294 211.4911 111 36.7335 10 
Hmox1 1366.73 460.719 1181.924 -906.011 27 ####### 24 
Jmjd2a 456.9127 257.482 381.7981 -199.431 113 ####### 24 
LOC100045405 632.4607 1016.55 1212.991 384.0883 71 12.0585 18 
Mtap6 2416.568 3740.87 3498.963 1324.301 14 18.8519 16 
Nfic 471.4015 824.266 920.268 352.8641 80 10.9582 19 
Nrk 765.6023 1346.22 1264.095 580.6197 40 336.687 1 
Peg3 1230.301 1881.76 1620.805 651.461 35 22.122 15 
Pop4 8059.39 5361.2 6662.532 -2698.19 8 -1.4376 23 
Prmt1 24504.9 9644.31 21487.24 -14860.6 1 ####### 24 
Rn18s 8297.79 14056.5 13853.01 5758.67 2 9.9987 21 
scl000972.1_0 456.4228 715.201 794.9742 258.7779 98 108.35 5 
Ttn 471.2359 773.904 959.9691 302.6682 87 336.687 1 
Usp40 572.353 879.668 845.3895 307.3151 85 58.2364 8 
Section 3:  
+/Loa v Loa/Loa           
 
  
Dcn 6771.753 7185.81 4609.991 -2575.81 9 -30.054 5 
E430033B07Rik 955.5 1134.48 1722.673 588.189 39 110.428 3 
Eif2s3y 165.0472 517.901 800.116 282.2151 90 20.2864 7 
Klc1 7438.797 6275.12 2454.743 -3820.38 4 -45.904 4 
Ppp1r12a 1170.69 1517.88 2446.846 928.968 24 336.687 1 
Slc4a1 2067.334 1661.36 2624.223 962.866 22 24.4116 6 
Xist 3145.592 3236.25 292.1439 -2944.1 5 -334.19 2 
 
Appendix: Microarray data from wild-type, +/Loa and Loa/Loa E13 brains. Genes identified as 
up or down-regulated in +/Loa and Loa/Loa when compared to wild-type are listed (left). Gene 
expression readings are listed for wild-type (purple), +/Loa (peach) and Loa/Loa (blue). 
Difference in signal from wild-type is shown in yellow for Loa/Loa (section 1), +/Loa (section 2) 
and +/Loa v Loa/Loa (section 3). Positive numbers indicate up-regulation whilst negative 
numbers indicate down-regulation. Ranks were allocated (green) depending on the difference in 
signal between the genotypes. Diff. scores indicating reproducibility across samples are shown. 
Scores above 30 indicate good reproducibility (pink) whereas below 30 is poor (light blue). 
Ranks based on diff. scores are shown far right. 
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